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Abstract: Development of an anastomotic leak (AL) following intestinal surgery for the treatment of
colorectal cancers is a life-threatening complication. Failure of the anastomosis to heal correctly can
lead to contamination of the abdomen with intestinal contents and the development of peritonitis.
The additional care that these patients require is associated with longer hospitalisation stays and
increased economic costs. Patients also have higher morbidity and mortality rates and poorer
oncological prognosis. Unfortunately, current practices for AL diagnosis are non-specific, which
may delay diagnosis and have a negative impact on patient outcome. To overcome these issues,
research is continuing to identify AL diagnostic or predictive biomarkers. In this review, we highlight
promising candidate biomarkers including ischaemic metabolites, inflammatory markers and bacteria.
Although research has focused on the use of blood or peritoneal fluid samples, we describe the use of
implantable medical devices that have been designed to measure biomarkers in peri-anastomotic
tissue. Biomarkers that can be used in conjunction with clinical status, routine haematological and
biochemical analysis and imaging have the potential to help to deliver a precision medicine package
that could significantly enhance a patient’s post-operative care and improve outcomes. Although no
AL biomarker has yet been validated in large-scale clinical trials, there is confidence that personalised
medicine, through biomarker analysis, could be realised for colorectal cancer intestinal resection and
anastomosis patients in the years to come.
Keywords: colorectal cancer; intestinal anastomosis; anastomotic leak; biomarkers; precision medicine
1. Introduction
Colorectal cancer is the fourth most commonly diagnosed cancer in the world, with
~1.8 million new cases and ~0.7 million cancer-related deaths occurring per year. The
disease accounts for 10% of all newly diagnosed cancers, meaning it is a significant social
and economic burden for many countries throughout the world [1]. In this review, we
briefly discuss disease staging, colorectal cancer treatments, pathophysiology of normal
intestinal healing and the consequences of abnormal intestinal healing. We then go on
to describe in depth how this knowledge has led to the identification of diagnostic and
predictive biomarkers of anastomotic leakage, which could be used to provide a precision
medicine approach for managing colorectal cancer patients.
2. Colorectal Cancer Staging and Treatment
Before instigating treatment, patients undergo investigations to define the stage of
the cancer. This is typically done using the tumour, node, metastasis (TNM) classification
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system (developed by the Union for Interventional Cancer Control) whereby data are
collected from physical examinations, imaging and endoscopy. Pathological classification
will be based on histopathology from biopsy samples typically obtained during endoscopy.
Depending on disease stage, various treatment options are available; however, for curative
intent strategies, surgery will be the treatment of choice. UK estimates indicate that 66% of
colon cancer and 63% of rectal cancer patients will receive surgery as part of their primary
care [2]. Surgery encompasses the excision of diseased intestinal segments containing
the tumour (resection) with the subsequent re-joining of the disease-free intestinal ends
(anastomosis). This intestinal resection and anastomosis procedure can be performed
either with hand-placed sutures, automatic stapling devices or through robotically assisted
techniques. Regardless of which technique is used, the procedure aims to re-establish
luminal and mural intestinal continuity. Records from the Association of Coloproctol-
ogy of Great Britain and Ireland (ACPGBI) have shown that, within Ireland and the UK,
~20,000 patients undergo a large bowel resection and anastomosis every year. The majority
of these procedures are performed to treat colorectal cancers. Colorectal cancer patient
outcomes have improved over the years through advances in peri-operative management,
the use of neoadjuvant and adjuvant radiotherapy and chemotherapy and through modifi-
cations of the surgical procedure. These advancements have undoubtably contributed to
the improved 5-year survival rate, which is now almost 60% [2]. Unfortunately, no matter
how safe the surgical procedure is regarded to be, complications can still occur. One such
life-threatening complication that typically occurs following failure of the anastomotic site
to heal correctly is termed an anastomotic leak (AL).
3. Anastomotic Leaks
The exact definition of what an AL is continues to be debated in the literature. The
UK Surgical Infection Study Group defined an AL as ‘a leak of luminal contents from a
surgical join between 2 hollow viscera’ [3]. However, a subsequent review of 97 papers
highlighted a lack of definition consistency between studies, with 56 different terms being
identified [4]. The lack of standardised terminology creates problems when comparing
results generated between different studies. A more recent attempt by the International
Multispecialty Anastomotic Leak Global Improvement Exchange Group has re-defined
an AL as ‘a defect of continuity localised at the surgical site of the anastomosis, which
creates a communication between intra-luminal and extra-luminal compartments.’ Using
this classification method, three grades of AL, increasing in severity from A to C, have been
described. Whereas grade A can be left untreated, grade B requires medical management
and grade C requires revision surgery [5,6].
Whatever the definition used, an AL is typically diagnosed 5–8 days post-surgery,
although some case reports have demonstrated that a delayed presentation beyond 30 days
is possible [7]. While AL can occur in up to 24% of patients undergoing distal rectal
surgery, combined rates for surgery performed at any level of the intestinal tract are
accepted to be ~6–7% [8,9]. The development of an AL not only results in increased
morbidity [10–12] and 30-day mortality rates [13], but in cancer patients, it has also been
associated with higher local recurrence rates and decreased long-term survival, but not
with distant recurrence [8,14–17]. One large study involving 1984 colorectal cancer patients
showed that 5-year cancer-specific survival was 57.4% in those that developed an AL
compared with 72% that recovered uneventfully. The 5-year local recurrence rates were
also increased from 1.9% to 4.7% in those that developed an AL [18]. Several explanations
for these poorer survival times and increased local recurrence rates have been proposed.
As viable cancer cells have been identified within the intestinal lumen and on staple/suture
lines, it is possible that, following an AL, these cells could exfoliate to extra-luminal tissues.
Implantation of these cells in the serosal surface of the intestine, peritoneum or pelvis could
lead to the development of local recurrence [19–25]. The inflammatory response related
to an AL has been proposed to stimulate tumour proliferation and evolution to distant
metastasis [26–30], with elevated levels of inflammatory markers such as C-reactive protein
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(CRP) associated with higher recurrence rates and impaired disease-free survival [31,32].
Intra-abdominal bacterial infections have also been suggested to stimulate neoangiogenesis,
which may increase the risk of disease recurrence [33].
Revision surgery will be required in ~85–95% of AL patients, with 50% of symptomatic
AL cases requiring permanent stoma formation [34]. Complications such as multi-organ
failure, pneumonia, renal and cardiac issues, localised/generalised sepsis, wound infec-
tions and surgical site dehiscence are also commonly encountered secondary to an AL [11].
The intensive care and revision surgery needed to manage these conditions, as well as
the AL itself, increases hospitalisation periods [35,36] and total treatment costs [36–41].
If a patient develops an AL, then early diagnosis is essential to decrease mortality rates
and achieve a positive outcome [7,42–45]. One study suggested that a 2.5-day delay in
instigating AL-specific treatments increased mortality rates from 24 to 39% [13], while a
further study identified that a 7.6% decrease in survival was associated with every hour of
delay from septic shock onset to when antibiotics were administered [46].
4. Intestinal Healing
Research into anastomotic healing and AL development has been acknowledged
as a priority by numerous healthcare providers, including the National Health Service,
National Institute for Health Research, the ACPGBI and the Colorectal Therapies Healthcare
Technology Co-operative. Following a resection and anastomosis, intestinal healing has
been described to occur in four stages [47–49].
â Stage 1. Haemostasis. Occurring immediately after intestinal injury, this stage in-
volves platelet and coagulation cascade activation.
â Stage 2. Inflammation. Occurring within 10 days after intestinal injury, this stage
involves surgical site recruitment of lymphocytes, neutrophils and macrophages.
â Stage 3. Proliferation. Occurring from 5 to 21 days after intestinal injury, this stage
involves intestinal re-epithelisation through fibroblast recruitment and endothelial
cell proliferation.
â Stage 4. Remodelling. The final stage of intestinal healing occurs from 21 days after
intestinal injury and continues for up to 1 year. Here, collagen deposition and tissue
remodelling can restore intestinal integrity.
5. Anastomotic Leak Pathophysiology and Risk Factors
In contrast to the well-documented and characterised stages of uneventful intestinal
healing, relatively little is known about AL pathophysiology. Studies, however, have iden-
tified several surgical and patient-related risk factors that can influence AL development
(Table 1) [8,9].
Table 1. Risk factors associated with the development of an anastomotic leak.




























Patient age as well as gender have been identified as AL risk factors, with men and
patients of either sex >60 years old being at increased risk of AL. Although the exact reason
for this is unknown, it is thought that the narrower male pelvis and androgenic hormonal
effects on the intestinal microvascular blood supply may play roles in AL development
in male patients [50–55]. Multiple studies have also shown that the American Society of
Anaesthesiologists (ASA) fitness score is also an independent AL risk factor. Patient scores
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≥III are associated with a 2.5-fold increased AL risk [55,56]. ASA scores are generated
using multiple patient-specific factors including nutritional status and medical history,
which have themselves been identified as independent AL risk factors.
Adequate nutrition is an important factor for intestinal healing as it contributes to
collagen synthesis and immune responses. Various studies have shown that patients
who are malnourished (including obese patients), have pre-operative weight loss [57–59],
anaemia or low albumin levels are at increased risk of AL [60,61]. Neo-adjuvant, pre-
operative chemo-radiotherapy has also been shown to be an independent risk factor for AL.
Radiotherapy causes poor intestinal healing and increased fibrosis by damaging the local
intestinal vascular system and impairing fibroblast function [51,62–64]. Pre-operative blood
transfusions, advanced tumour stage and tumours >5 cm have also been identified as AL
risk factors [56,65]. Currently, there is no consensus as to whether metabolic diseases, such
as diabetes mellitus, increase AL risk through impaired wound healing [66,67]; however,
patients with pre-existing renal disease, or those that smoke or drink alcohol excessively,
have been identified as high-risk for AL development [67–70].
Although the intestinal microbiome plays an important role in the health, physiology
and healing of the intestine [71], specific bacterial infections have been demonstrated to
increase AL risk. One early study exhibited that rats inoculated with Pseudomonas aeruginosa,
24 h following gastrectomy and oesophagoduodenostomy, demonstrated higher AL rates
compared with rats that were also inoculated with Pseudomonas aeruginosa but received peri-
operative antibiotics (95% vs. 6%) [72]. A subsequent human clinical trial supported these
pre-clinical results by showing that reduced AL incidence (10.6% vs. 2.9%) and mortality
rates (10.6% vs. 4.9%) were achieved in gastrectomy and oesophagojejunostomy patients
treated with peri-operative antibiotics [73]. The authors suggested that antibiotics may play
a protective role against AL development. Although the mechanisms by which bacterial
infections contribute to AL development are not fully understood, matrix metalloprotease
(MMP) activation and collagenolytic substances produced by anastomotic site bacteria may
play a role [74]. Using a pre-clinical rat model, one study demonstrated that antibiotics,
with efficacy against Enterococcus faecalis (a bacterial strain with high collagen-degrading
activity), placed topically at the colorectal anastomotic site, reduced AL incidence, whereas
intravenous antibiotics failed to eliminate anastomotic site Enterococcus faecalis and reduce
AL rates [75]. Following these results, MMP inhibitors have undergone investigations
for their ability to prevent AL. One meta-analysis concluded that although anastomotic
strength in animal models can be improved through MMP inhibitors, human clinical trials
have yet to demonstrate a role in decreasing AL rates [76].
5.2. Surgery-Related Factors
A significant AL risk factor is the anatomical location of where the anastomosis is
performed in the gastrointestinal tract [77]. One systematic review identified that the
highest rate of AL occurred in coloanal and colorectal anastomoses (5–19%). This rate
was significantly greater than that seen in enteroentero (1–2%), ileorectal (3–7%), ileocolic
(1–4%) and colocolic (2–3%) anastomoses [78]. Multiple studies have also shown that
anastomotic position in relation to the anal verge is important; cancer resections performed
in the mid/low rectum [79] or <6 cm from the anal verge [80] have been associated with
significantly higher AL rates. Patients that require an emergency resection and anastomosis
at any level of the gastrointestinal tract are also at higher risk [55].
When considering the surgical procedure itself, studies have failed to show AL rate
differences between hand-sewn or stapled anastomoses [81,82] or between open abdominal
procedures or laparoscopic surgery [83–85]. Studies investigating the advantages of roboti-
cally performed colorectal anastomoses have failed to show AL rate differences compared
with laparoscopic resections [86–88]. Conflicting results have been reported as to what
extent surgical experience can influence AL rates. Whilst one study demonstrated that
surgery performed by high-volume colorectal surgeons may reduce AL, another failed to
demonstrate AL rate differences when surgeon experience was taken into account [89,90].
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Multiple firings of the stapling device and surgical times >3 h have also been identified as
AL risk factors [56,65].
Poor intestinal tissue oxygenation (partial pressure of O2 in tissue; ptO2) has also been
suggested to contribute to AL development. Iatrogenic surgical disruption of the peri-
anastomotic microvascular blood supply or tension at the anastomotic site can compromise
intestinal tissue perfusion. If local blood supply is unable to meet intestinal O2 require-
ments, this situation can lead to peri-anastomotic ischaemia and necrosis [48,49,91,92].
Adequate ptO2 is also required for collagen production, with O2 levels <15–20 mmHg
associated with compromised synthesis. As submucosal collagen is the predominant tissue
layer for anchoring sutures/staples in the early stages of anastomotic healing, inadequate
collagen production could contribute to AL incidence [93].
6. Diagnosis
As already mentioned, early AL diagnosis and subsequent management is essential to
reduce patient morbidity and mortality. Unfortunately, early diagnosis can be extremely
difficult as there are no pathognomonic signs which can be specifically attributed to an
AL. Patients can initially be asymptomatic while non-specific clinical signs can range
from abdominal pain, ileus, pyrexia and cardiorespiratory issues to acute organ failure
and sepsis. These wide-ranging clinical symptoms can be difficult to distinguish from
those caused by normal post-operative inflammatory and physiological responses [94].
Based on clinical assessments, one study demonstrated that 69% of AL patients had a
delayed diagnosis, of which the majority of patients presented with only cardiovascular
symptoms [95]. Clinical assessment, regardless of experience and training, is therefore
regarded as an inadequate technique for identifying high-risk AL patients or for its early
diagnosis [96].
As clinical signs cannot be relied upon for AL diagnosis, clinicians use a variety of
blood tests assessing inflammatory markers such as CRP and leukocytes. Unfortunately,
these markers are again non-specific, with raised levels commonly occurring secondary to
various post-operative complications, including chest, urinary and surgical site infections.
Rather than using individual markers, one study assessed leukocyte number, creatinine
levels, CRP levels, core temperature, urine production and systemic inflammatory response
syndrome components. This combined approach was able to reduce the delay in AL
diagnosis from 4 to 1.5 days [13]. Scoring systems have also been designed to predict
AL risk. One study generated a scoring system based upon data from 1060 patients
who underwent an anterior resection. Using known AL risk factors (intra-operative
haemorrhage, gender and level of anastomosis), this study classified patients into low-
(0–1), intermediate- (2–3) and high-risk (4–5 score) cohorts with AL rates of 1.9%, 8% and
16.1%, respectively [97]. The Colon Leak Score, which incorporates surgical and patient-
specific risk factors, has also been developed to predict AL risk [98]. As well as these
predictive scoring systems, others have looked to diagnose AL. The Dutch Leakage Score
and the Modified Dutch Leakage Score have, unlike the previously mentioned predictive
scoring systems, undergone clinical validation. Using clinical and physiological data with
laboratory results, the derived Dutch Leakage Score has been shown to have a sensitivity of
97%, specificity of 53.5%, positive predictive value (PPV) of 16.1% and negative predictive
value (NPV) of 99.5% for AL diagnosis (depending on the score cut-off values used).
Meanwhile, the much simpler Modified Dutch Leakage Score, again depending on the
score cut-off, could still produce a sensitivity of 97%, specificity of 56.8%, PPV of 17.2% and
NPP of 99.5% for AL diagnosis [13,99,100].
Current clinical practices for AL diagnosis rely on abdominal imaging (plain radio-
graphs, computed tomography (CT) scans or water-soluble contrast enemas (WSCE)), in
conjunction with clinical and biochemical evaluation. Although CT is perhaps the most
commonly used imaging modality for AL diagnosis, studies have shown it to have variable
sensitivity and specificity. One retrospective study reported that only 47% of CT scans per-
formed within 72 h of a patient requiring repeat surgery were diagnostic for an AL [101]. CT
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and rectal contrast radiography have been shown to have comparable sensitivity (57–60%)
and specificity (100%) rates for AL diagnosis, greater than those of using clinical assess-
ments alone (50% sensitivity and 89% specificity). The authors of this study suggested that
whilst these imaging techniques gave false negative results, both were equally good for AL
diagnosis [102]. Another large study in the 1970s analysed data from almost 2000 anterior
resection patients. From the results, the authors suggested that although contrast studies
could provide an indication of leak severity, they offered no diagnostic advantage over
sigmoidoscopy and/or digital rectal examination, especially in patients that received a
low anastomosis [103]. WSCE have also been shown to have higher false positive rates
compared with digital rectal examination (6.4% vs. 3.5%) [104]. As plain abdominal X-rays
can identify disrupted staple lines, a further study suggested that WSCE may only be
required when intact staple lines, identified on radiographs, occur in conjunction with
unrelenting clinical signs [105]. Another study demonstrated that WSCE used in colorectal
or left-sided colonic anastomoses had sensitivity and specificity values of 52.2% and 86.7%,
respectively, leading the authors to suggest that the test had little impact on improving
early patient morbidity [106]. A retrospective study using data from colorectal patients
demonstrated that WSCE detected ~83% of leaks, whereas only ~15% were identified using
CT. This difference was most apparent for distal ALs, leading the authors to conclude
that WSCE may be more beneficial in evaluating low anastomoses [107]. Several studies
have highlighted that CT-based AL diagnosis is challenging [107,108]. These studies have
indicated that the only reliable CT sign of an AL was the presence of peri-anastomotic
liquid and air; extravasated contrast material from the intestinal luminal into the abdomen
was not always present. Similarities in CT data between patients with and without AL
were also observed. These results indicated that CT interpretation requires an experienced
radiologist, and that radiological interpretation should be performed with knowledge of
clinical data.
As a result of these conflicting findings, there is still no definitive consensus on which
imaging modality should be used for AL diagnosis. Furthermore, a reluctance by clinicians
to perform multiple scans due to cost, logistics and patient radiation exposure, combined
with inherent delays incurred from the time of imaging to the interpretation of results, can
significantly hinder prompt AL diagnosis. As a result of these imaging-based limitations,
researchers and clinicians are looking at novel AL predictive and diagnostic methods that
could lead to a more refined, precision medicine approach to patient management (Table 2).


















7. Precision Medicine, Prognostic, Predictive and Pharmacodynamic Biomarkers
Current post-operative management of intestinal resection and anastomotic patients
is principally focused on improving global and local tissue perfusion [109]. Post-operative
preservation of normovolaemia [110], normothermia [111], delivering supplemental O2 [112]
and goal-directed intravenous fluid therapy [113,114] can all reduce morbidity and improve
outcomes. A pig model has also shown that intravenous colloids can increase perfusion
and ptO2 in normal and peri-anastomotic colonic tissue [115]. Although these generic
peri-operative patient management strategies may help to promote anastomotic healing
and decrease AL rates, patient outcomes are likely to be improved by clinicians adopting a
precision or personalised peri-operative treatment strategy.
Precision and personalised medicine encompass the idea that optimal patient manage-
ment requires patient- and/or disease-specific factors to be considered. Although similar,
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specific personalised and precision medicine definitions highlight key differences in their
concepts; whereas personalised medicine considers individual patient genetics, patient
beliefs, social background, preferences and attitudes, precision medicine emphasises the
importance of data collection and analysis [116]. Although both concepts have subtle
differences, the term ‘precision medicine’ has become more extensively used. This has
principally been due to unease amongst clinicians thinking that patients might misinterpret
‘personalised medicine’ as a technique by which drugs are developed for specific individ-
uals [117,118]. Perhaps the clearest definition of what precision medicine is came from
The National Research Council in America, who described it as ‘the tailoring of medical
treatment to the individual characteristics of each patient . . . to classify individuals into
subpopulations that differ in their susceptibility to a particular disease or their response to
a specific treatment. Preventative or therapeutic interventions can then be concentrated on
those who will benefit, sparing expense and side effects for those who will not’ [118]. To
achieve the aims of this precision medicine concept, research has largely focused on the
use of patient- or disease-specific biomarkers.
A biomarker can be any measurable tissue or bodily fluid biological substance that
represents normal or abnormal physiological processes or pathological conditions [119].
There are four classical biomarker categories [120–122]:
1. Diagnostic. Identifies the presence of disease;
2. Predictive. Indicates the likely benefit of a specific treatment;
3. Prognostic. Indicates patient outcome, irrespective of treatment;
4. Pharmacodynamic. Allows monitoring treatment effectiveness.
A clinically useful biomarker is one that is obtained non-invasively, is easily assayed
and provides results that have high sensitivity and specificity. Broadly speaking, for AL,
these can be biomarkers of ischaemia, inflammation, tissue repair and the presence of
bacterial contamination (Figure 1). All these potential biomarkers can be assessed through
either blood or peritoneal fluid samples. These types of biomarkers have the potential to be
assessed either intra-operatively, to predict which patients are at high risk of complications,
or post-operatively, to identify which patients may require additional management to
prevent an AL from developing or allow for its early diagnosis. In conjunction with clinical
status, physiological parameters and imaging results, these types of biomarkers could
be used to achieve a precision medicine approach for patients undergoing a resection
and anastomosis.
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treatment of colon cancer. (IL; interleukin, CRP; C-reactive protein, PCT; procalcitonin, WBCC; white
blood cell count, I-FABP; intestinal fatty acid binding protein, MMP; matrix metalloproteinases, TIMP;
tissue inhibitor of metalloproteinases, VEGF; vascular endothelial growth factor, EGF; epidermal
growth factor, PDGF; platelet-derived growth factor, LPS; lipopolysaccharide). Figure created
in Biorender.
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8. Intra-Operative Techniques
During surgery, immediately following anastomosis, surgeons evaluate intestinal
integrity through assessment of anastomotic doughnut completeness, air leak testing
and/or endoscopic visualisation. Although air leak testing alone can reduce post-operative
AL rates from 14% to 4% [123,124], intra-operative endoscopy can be performed with an
air leak test and allows the surgeon to assess for vascular insufficiency, staple line bleeding,
adequate tumour margins, iatrogenic intestinal injury and missed pathology [125–127].
One study demonstrated that routine intra-operative endoscopy identified anastomotic
issues that required correcting in 10% of patients [125].
Further intra-operative assessment techniques have predominantly focused on intesti-
nal ptO2 levels as a way of predicting which patients are at high risk of AL. Although
surgeons evaluate macroscopic tissue appearance (colour, intestinal bleeding and palpable
mesenteric pulses) as a surrogate for intestinal perfusion, these subjective techniques are
unable to predict AL risk. To overcome this issue, various techniques have been developed
to objectively measure intestinal tissue oxygen saturation (StO2) (visible light and near
infrared spectroscopy) [128,129], tissue perfusion (laser fluorescence angiography, laser
Doppler flowmetry) [130,131] and arterial haemoglobin O2 saturation (wireless handheld
pulse oximeters) [132].
Visible light spectroscopy used in colorectal anastomoses has demonstrated that
reduced tissue O2 saturation immediately after resection can predict AL. Interestingly, this
study also showed that patients who recovered uneventfully demonstrated a significant
intra-operative rise in StO2 in the proximal part of the anastomosis, which was not seen in
those who developed an AL [128]. Animal studies have supported these results through
comparing intestinal tissue oxygenation with staple size and by using wireless pulse
oximeters [132,133]. In a recent human study, intra-operative colonic O2 saturation was
measured with a pulse oximetry device placed on the colonic wall and evaluated for
its ability to assess tissue viability and predict AL in colorectal anastomotic patients.
The results showed that the risk of developing an AL was 4.2 times higher when post-
anastomotic colonic StO2 was ≤90% of the pre-resection values. The authors suggested
that low intra-operative colonic StO2 values were associated with AL occurrence [134].
Laser fluorescence angiography has also been shown, in a retrospective clinical trial of
402 patients, to reduce the number of patients that developed an AL. Out of the 22 patients
that developed an AL, only seven (3.5%) were in the imaging group, compared with 15
(7.5%) in the control group [130]. Near infrared (NIR) fluorescent imaging has also been
investigated for its intra-operative use as the energy range it uses is capable of penetrating
deep into the intestinal walls and mesenteric tissues without causing thermal damage [135].
Coupled with indocyanine green, veins, arteries and capillaries can be identified, with
vascular streams being used as an approximation of tissue perfusion. In animal models,
this technique has been shown to predict the viability of ischaemic intestine [136] and an
ongoing human clinical trial is assessing the use of NIR laparoscopy–indocyanine green to
minimise leak occurrence compared with conventional white-light laparoscopy [137].
Clark O2 electrodes have also been investigated for their ability to measure intra-
operative intestinal ptO2. In pre-clinical animal models, gradual intestinal perfusion
reduction through sequential accurate intestinal artery ligation demonstrated that intestinal
ptO2 measured before performing an anastomosis could predict AL occurrence [93,138,139].
In humans, Clark O2 electrodes have been used to provide intra-operative ptO2 reference
values for the majority of the gastrointestinal tract [140]. Clinical trials have also shown
that colonic ptO2 of less than either 20 mmHg, 50% of pre-resection values, 15% of arterial
oxygen partial pressure (PaO2) or 40% of ptO2 at a control site were all associated with
AL development. This study provided evidence that Clark O2 electrodes could be used to
measure peri-anastomotic colonic ptO2 before, during and immediately after performing a
resection and anastomosis and that, using defined cut-off values, the risk of developing an
AL could be predicted [93].
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Although these intra-operative techniques are well established, there are no standard
guidelines as to which should be used. As a result of this, there is considerable variation
between surgeons and hospitals [141]. To begin to address this, the European Society of
Coloproctology Safe-anastomosis Programme in Colorectal Surgery (EAGLE) has been set
up. Launched in 2019, this is an international, multicentre, cluster randomised controlled
sequence study. EAGLE aims to recruit at least 2000 surgeons from 300 hospitals in order
to collect data from >4500 patients who have undergone a right colectomy and ileocecal
resection. The study results will be used as a quality improvement programme aimed
at pre-operative risk stratification and standardising surgical techniques used for these
patients [142].
9. Post-Operative Techniques
Many pre-clinical and clinical research studies have provided clear evidence that intra-
operative assessment of anastomotic integrity and peri-anastomotic tissue perfusion can
predict AL risk. Unfortunately, these techniques ultimately fail to encompass a precision
medicine approach to patient care as they cannot be used to assess intestinal healing in the
post-operative period. To overcome this, researchers are now looking at biomarkers which
can be used post-operatively that allow continual patient monitoring and assessment of
intestinal healing. These techniques have the goal of identifying high-risk patients and
provide a means of early AL diagnosis.
10. Biomarkers of Ischaemia
Under aerobic conditions, adenosine triphosphate (ATP) is efficiently generated during
the conversion of glucose to pyruvate through glycolysis and the Krebs cycle. However,
when O2 and glucose supply are limited and unable to meet the metabolic demands
of a tissue, cells have to rely on anaerobic metabolism. Here, ATP is generated less
efficiently from pyruvate being converted into lactate, with CO2 being released in the
process. Ischaemic tissue microenvironments are therefore typically regarded as having low
glucose and pyruvate levels in the presence of high lactate concentrations. Accumulated
amounts of CO2 will also cause a reduction in tissue pH. If ischaemic conditions are
prolonged, cells become damaged and, with the breakdown of their cell membranes,
phospholipids are released, generating glycerol and free fatty acids. Although these
individual ischaemic biomarkers can be measured, calculating lactate/pyruvate ratios
(LP ratio) can characterise the aerobic/anaerobic metabolic balance, with higher values
signifying ischaemia. Unfortunately, assessment of ischaemic biomarkers in blood has
been shown to lack specificity for AL diagnosis [143]. To address this, ischaemic biomarker
levels in peritoneal fluid have been investigated. Animal studies using microdialysis
catheter fluid (small probes with dialysis membranes inserted into/onto the intestine)
have shown that lactate, glucose and glycerol levels change with the metabolic alterations
that occur in hypoxic [144] and ischaemia [145] conditions. Most human clinical studies
have now focused on assaying ischaemic biomarkers in microdialysis catheter fluid or
peritoneal fluid from abdominal drains. In a pilot study of eight patients undergoing right
hemicolectomy, metabolic changes consistent with visceral ischaemia were identified in
microdialysis catheter fluid several hours before clinical signs of AL became apparent [146].
A subsequent study characterised microdialysis catheter fluid reference ranges for the first
45 h following surgery in patients that recovered uneventfully from a variety of elective
gastrointestinal operations [147].
10.1. Lactate/Pyruvate Ratio
High peritoneal LP ratios have been associated with AL in multiple clinical studies.
In one study, patients undergoing anterior rectal resections had their LP ratio and glucose
levels assessed for the first 6 days following surgery. Results indicated that the LP ratio
in patients that developed an AL was significantly higher on days 5 and 6 following
surgery. Unfortunately, due to low patient numbers, LP ratio cut-off values for predicting
J. Pers. Med. 2021, 11, 471 10 of 29
an AL could not be determined [148]. A further study using microdialysis catheters in
45 low anterior resection patients obtained fluid samples from the anastomotic site every
4 h. Lactate and LP ratios were found to be significantly raised in the four patients that
developed an AL. Interestingly, in three patients who developed an AL >10 days following
surgery, raised lactate and LP ratios were detected several days before clinical symptoms
developed. Lactate levels in the remaining AL patient increased 18 h before clinical signs,
with LP ratios only becoming elevated once clinical symptoms became evident [149]. A
similar study again using microdialysis catheters obtained peritoneal fluid samples from
patients every 2 h for the first 2 days, then every 4 h until 7 days following colorectal
surgery. Higher peritoneal lactate and LP ratios and lower glycerol levels were seen
immediately following surgery in patients that went on to develop an AL. These levels
became significantly raised by the 4th day following surgery [150]. In another study that
contained colorectal anastomoses, abdominal aortic aneurysm repairs, gastric procedures
and cholecystectomy, results showed that increased peritoneal LP ratios and decreased
glycerol levels were associated with ‘major intra-abdominal complications’ [151]. A further
study involving 88 patients who underwent various abdominal procedures, including an
intestinal resection and anastomosis, had their post-operative peritoneal and serum lactate
levels assessed. Patients that had peritoneal/serum lactate level >4.5 or peritoneal lactate
level >9.1 mM in the presence of pyrexia (>38.3 ◦C), raised white cell count (>12 × 109/L),
delayed passage of flatus (>72 h) and abdominal pain by the 4th day post-surgery were
significantly associated with post-operative complications that required revision surgery
(AL were included in this group) [152]. In slight contrast to these results, a further study
which measured lactate, pyruvate, glycerol and glucose levels every 4 h for 5 days after
patients underwent a left-sided colorectal anastomosis demonstrated that, in the three AL
patients, lactate levels but not LP ratios were significantly elevated. Interestingly, in all
the patients which developed an AL, the raised lactate levels occurred in the first 3 days
following surgery [153].
A recent prospective study has also compared peritoneal lactate, pyruvate, glucose
and glycerol assessment with daily clinical scoring (leak scores and the Dutch Leakage
Score system). This study showed that, in cases of AL, peritoneal lactate concentration
increases over time and its assessment can have greater sensitivity, specificity and better
PPV and NPV than clinical scoring systems. The median day for an AL diagnosis with
a change in lactate ≥6.3 mM was 1.6, whereas for leak scores and for the Dutch Leakage
score system, it was 3.3 and 7 days, respectively [154].
10.2. pH
To investigate pH as an ischaemic AL biomarker, one study has measured intestinal
mucosal pH with tonometry. pH measurements were taken using a catheter placed at a
colorectal anastomosis site through the anus. Imaging performed on the 6th day following
surgery was used for symptomatic and asymptomatic AL diagnosis. Results indicated that
in the first 24 h, mucosal pH values were significantly reduced in patients who subsequently
developed an AL. Using a pH cut-off value of <7.28 in the first 24 h was associated with
a 22-times greater risk of AL, with a sensitivity of 28% and specificity of 98% for AL
prediction [155]. A further study measured peritoneal drain fluid pH in the first 12 days
following colorectal surgery. Similar to the previous study, results indicated that pH values
were significantly lower in patients which developed an AL that needed revision surgery.
Using a cut-off pH value of <6.978 on the 3rd day following surgery had a sensitivity of
98.7% and specificity of 94.7% for predicting an AL. Interestingly, a decline in pH was seen
in all patients preceding their AL diagnosis [156].
10.3. Tissue Oxygenation
The intra-operative use of Clark O2 electrodes, as previously described, has been inves-
tigated for their ability to predict AL. However, these studies overlooked their applications
for post-operative use. The concept of using miniaturised Clark O2 sensors to provide post-
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operative intestinal ptO2 measurements has begun to be investigated by the Implantable
Microsystems for Personalised Anti-Cancer Therapy (IMPACT) programme. Our group
has developed novel implantable miniaturised Clark-type electrochemical O2 sensors [157]
and methylene blue-based electrochemical and ion sensitive field-effect transistor (ISFET)
pH sensors [158]. The idea that these sensors could be placed intra-operatively around the
anastomotic site and be left in situ would allow clinicians to continuously monitor peri-
anastomotic intestinal ptO2 and pH throughout the post-operative recovery period. This
type of continuous monitoring system would help to identify patients at risk of developing
an AL due to poor or deteriorating peri-anastomotic intestinal ptO2. It would also allow
clinicians the ability to assess the efficacy of interventions designed to improve intestinal
ptO2 and prevent a leak from occurring. The electrochemical O2 sensor has undergone
initial in vivo validation in a rat model [159]. The results from this study showed that sen-
sors, placed on intestinal serosal surfaces, were able to provide continuous, real-time ptO2
readings. These sensors also recognised and reported dynamic intestinal ptO2 changes
that occurred with hypoxaemic and ischaemic challenges. The authors suggested that
although further research is required, this pre-clinical study demonstrated the potential
use of miniaturised implantable medical devices for intestinal surgery.
11. Biomarkers of Inflammation
A wide range of inflammatory mediators, such as acute-phase proteins, cytokines
and growth factors, are released into the peritoneal cavity and bloodstream following
abdominal surgery [160]. If these substances are to be used as part of a precision medicine
approach in intestinal surgery, then studies have to show their ability to differentiate the
normal physiological responses to surgery from clinically important complications such
as AL.
11.1. C-Reactive Protein, Albumin and Procalcitonin
CRP, a hepatic acute-phase reactant with a half-life of 19 h, is typically found at low
levels (0.8 mg/L) in the blood of healthy individuals. CRP levels can rise dramatically in
response to inflammatory cytokines such as interleukin (IL)-6 (IL-6), tumour necrosis factor-
α (TNF-α) and IL-1β. This can occur as part of an acute-phase inflammatory response due to
infection, tissue damage and neoplasia [161]. Post-operative serum CRP levels are routinely
assessed as part of standard care practices to provide information on clinically significant
inflammation and post-operative complications. Unfortunately, its use in resection and
anastomotic patients is still contentious, with studies demonstrating poor CRP specificity
for AL diagnosis, with levels only becoming significantly raised when clinical symptoms
become apparent [162–164].
In contrast to these results, recent research has shown that serum CRP levels can
become elevated several days before clinical AL diagnosis and are significantly raised
in comparison to patients who have an uneventful post-operative recovery [165–177].
Currently, the main issue with using serum CRP levels for AL prediction or diagnosis is
the lack of definitive cut-off values. Cut-off values in these studies alone ranged from
123 to 245 mg/L, which were measured between 3 and 5 days following surgery. In a
meta-analysis of seven clinical trials which included 2483 patients, results suggested that
serum CRP cut-off values of 172 mg/L, 124 mg/L and 144 mg/L on the 3rd, 4th and 5th
days following surgery possessed an NPV of 97% for excluding an AL [178]. Furthermore,
in a recent prospective international study of 933 colorectal resection and anastomosis
patients, of which 41 developed an AL, serum CRP levels were assessed pre-operatively
and continued for 5 days post-surgery. Results indicated that a change in CRP levels
>50 mg/L over any 2 post-operative days had a sensitivity of 85% for diagnosing an AL
and an NPV of 99% for ruling it out. A change in CRP >50 mg/L between days 3 and 4 or
4 and 5 had an even higher specificity of 97%. The authors highlighted the value of CRP
trajectory assessment for its ability to rule out an AL [179].
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Albumin, also an acute phase protein, has been proposed as an indicator of surgical
stress and can be used to predict the development of post-operative complications [180].
Hypoalbuminemia has also been suggested to be an AL risk factor for colorectal resec-
tions as part of treatment for ovarian cancer [181]. A novel indicator, the C-reactive
protein:albumin ratio (CAR), has been used to identify patients at risk of post-operative
complications after colorectal surgery [182]. This study showed that CAR measurement
provided greater diagnostic accuracy than assessing CRP or albumin levels alone. In one
recent retrospective study of 1068 elderly colorectal anastomotic patients, the AL predictive
value of CAR was investigated. Using a pre-operative CAR cut-off value of 2.44, the assay
had a sensitivity of 61% and specificity of 80% for predicting an AL. Surgical time and
pre-operative CAR were also both identified as independent AL risk factors [183].
Procalcitonin (PCT), the prohormone of calcitonin, is produced by thyroid parafollic-
ular C-cells. PCT is typically found in low levels (<0.05 ng/mL) in the blood of healthy
individuals. Bacterial infections have been shown to induce PCT release from all differ-
entiated cell types, which can occur within 2–3 h following infection and is related to
the presence of bacterial endotoxins and inflammatory cytokines such as TNF and IL-6.
Patients with serum PCT levels >2 ng/mL have been associated with bacterial infections,
but levels >700 ng/mL can be seen in cases of severe sepsis [184]. Serum PCT levels, in
contrast to CRP, do not become raised secondary to inflammation of a non-infectious origin
and its use for early AL diagnosis has been investigated.
One study involving 157 colorectal resection and anastomotic patients demonstrated
that serum PCT levels in the range of 1.4–4.62 ng/mL measured on the 1st day following
surgery predicted those that subsequently developed an AL. These values were significantly
higher than that seen in patients who recovered uneventfully (0.09–0.44 ng/mL). Using
a PCT cut-off value of 1.09 ng/mL on the 1st day following surgery gave sensitivity and
specificity values of 87% for AL prediction. The authors suggested that PCT could be used
at this early post-operative time point to identify high-risk patients [185]. A similar study,
again involving colorectal cancer resection and anastomosis patients, demonstrated that
PCT measured on the 3rd day following surgery could identify patients at low risk of AL
development. Using 3.83 ng/mL as a PCT cut-off value gave a sensitivity of 75% and
specificity of 100% for AL prediction [168]. These results are supported by another study
that also concluded that PCT levels measured over the first 5 days following surgery are a
reliable predictor of AL after colorectal surgery. Using a PCT cut-off value of 0.31 ng/mL
on the 5th day following surgery was shown to have 100% sensitivity, 72% specificity, 100%
NPV and 17% PPV for AL. The authors suggested that patients with elevated serum PCT
levels on post-operative days 3–5 warranted further assessment before discharge [186].
These results have been supported in other studies [166,170].
Many of these studies assessed both CRP and PCT levels simultaneously and it has
been proposed that measuring both can improve AL diagnosis. In the recent PREDICS
study involving 504 colorectal resection and anastomosis patients, the study demonstrated
that a PCT cut-off value of 2.7 ng/mL had an NPV of 96.9% and specificity of 91.7% on
the 3rd day following surgery, whereas a cut-off value of 2.3 ng/mL on day 5 had an NPV
of 98.3% and specificity of 93% for AL diagnosis. CRP also exhibited good NPV 96.4% on
the 3rd day (cut-off value 169 mg/L) and 98.4% on the 5th day (cut-off value 125 mg/L).
Combined CRP and PCT assessment further improved AL diagnosis [170]. These results
have been supported by a more recent study that suggested that CRP and PCT levels were
higher on post-operative days 1–3 in patients who subsequently developed an AL. The
authors suggested that these markers could be used to allow early patient discharge in
those with low risk of developing an AL [187].
11.2. Cytokines, Tumour Necrosis Factor-α and Growth Factors
Cytokines such as IL-1, IL-6, IL-10 and TNF-α are polypeptides with known roles in
immune responses. In response to surgical trauma, they regulate physiological responses
and induce the production of hepatic acute-phase proteins, whilst, in response to sepsis,
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they can mediate systemic inflammatory responses [188–190]. Raised IL-1b, IL-6 and TNF-
α levels have also been associated with surgical stress, including lengthier operating times,
haemorrhage and high peritoneal bacterial counts [191–193]. Within the first few hours
following abdominal surgery, these substances are released from the surgical site. During
this period, studies have shown that peritoneal cytokine levels are raised to a greater
degree than serum levels. This provides evidence, similar to the ischaemic biomarkers,
that peritoneal rather than serum biomarker levels are more representative of localised
tissue changes [194,195]. In patients that have uncomplicated post-operative recoveries,
peritoneal cytokine levels typically decrease within 24 h following surgery [195]. However,
cytokine dynamics that occur with an AL follow a significantly different course.
Raised peritoneal levels of IL-6 and TNF-α have been shown in numerous studies
to occur as early as the 1st day following surgery in patients who go on to develop an
AL [148,196–199]. Further studies, however, have demonstrated that their levels only
become elevated from the 3rd post-operative day [200,201]. An important observation
from all these studies was that, in AL patients, IL-6 and TNF-α levels for the first 5 post-
operative days remained elevated, whereas, in patients that recovered uneventfully, their
levels remained low or even decreased. Although a further study observed no differences
between a control group and patients who developed an AL in their IL-6 and TNF-α levels
over the first 7 days following surgery, the results demonstrated that TNF-α levels rapidly
rose 24 h before a surgical diagnosis of AL was made [202]. A more recent case–control
study investigated serum and peritoneal IL-6 levels on the 2nd and 4th days following
colorectal surgery. In total, 30 AL and intra-abdominal abscesses (infection group) were
compared with 30 uneventful recovery patients (control group). These results demonstrated
that higher peritoneal levels in the infection group were seen on the 2nd and 4th days,
whereas serum levels only became significantly elevated on the 4th day [203]. A further
study identified that serum IL-6 levels on the 3rd post-operative day were significantly
elevated in AL patients with similar sensitivity to that of CRP. Interestingly, the relative
change in pre-operative to post-operative IL-6 levels was significantly higher in AL patients,
with granulocyte-colony stimulating factor also showing similar changes [204]. Increased
peritoneal levels of IL-1, IL-10, vascular endothelial growth factor, epidermal growth factor
and platelet-derived growth factor have also been suggested to occur in patients who
develop an AL and sepsis following colorectal surgery [148,193,196–198,201,203].
11.3. Leukocytes, Neutrophils and Intestinal Damage Markers
White blood cells (WBC) play a crucial role in wound healing through microorganism
elimination. It had been proposed that the WBC count (WBCC) can reflect the extent of
inflammation within the body or surgical site. As an AL creates significant inflammatory re-
sponses, several studies have investigated whether assessing leukocyte and/or neutrophil
numbers in blood can aid AL diagnosis.
In one retrospective study of 1187 colorectal cancer patients, CRP levels and WBCC
were assessed for the first 5 days following surgery. CRP levels, in line with other studies,
measured on the 4th day provided the highest diagnostic accuracy for identifying post-
operative complications, whereas WBCC contributed little information [174]. These results
were supported by other retrospective [176] and prospective studies [170]. A further study
demonstrated that in patients who developed an AL, increased WBCC only occurred after
6 days following surgery [165]. In a smaller study of 129 laparoscopic colorectal surgery
patients, systemic CRP levels and WBCC were assessed. Using a CRP cut-off value of
>200 mg/L on the 3rd day following surgery had a sensitivity of 68% and a specificity of
74% for predicting septic complications, whilst using a WBCC cut-off value of >12 × 109
on the 2nd day had a sensitivity of 90% and a specificity of 62%. The authors concluded
that systemic CRP levels and WBCC were poor early diagnostic markers for predicting
post-operative septic complications (including AL) [164]. Assessing neutrophil:lymphocyte
ratios (NLR) has also been described as a method for AL prediction. One study demon-
strated that NLR on the 4th day following surgery had prognostic value, with higher NLR
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identified in AL patients. An NLR cut-off value of 6.5 had a sensitivity of 69%, specificity
of 78%, PPV of 49% and NPV of 88% for AL diagnosis. NLR were also significantly higher
at this time point in patients who subsequently died in the post-operative period [171].
Calprotectin makes up ~60% of the cytosolic proteins found within neutrophils and
is a recognised marker of neutrophil activation [205]. Studies have begun to investigate
calprotectin as an inflammatory biomarker for early AL diagnosis. In one retrospective
study of 84 colorectal cancer patients, serum CRP and calprotectin levels were assessed
for 5 days following surgery. In patients that developed an AL, calprotectin levels became
significantly elevated on the 2nd day following surgery (588 ng/mL) compared to those
that went on to recover uneventfully (366 ng/mL). Calprotectin levels in AL patients also
remained elevated throughout the 5 days. Although the authors suggested that calprotectin
levels could be used to diagnose an AL, improved diagnostic accuracy was obtained when
combined calprotectin and CRP assessment was performed on the 3rd day following
surgery. This assay provided a sensitivity of 100%, specificity of 89%, positive likelihood
ratio of 9.09 and negative likelihood ratio of 0.00 [167]. Similar results have been seen in a
further study which identified raised pre-operative and post-operative calprotectin levels
on the 1st, 3rd and 5th days following surgery in patients which developed an AL, whereas
CRP levels only became elevated on the 3rd and 5th days, with no WBCC changes being
observed. The authors again suggested that combined calprotectin and CRP assessment
might aid early AL diagnosis [206].
Faecal calprotectin has also been used for assessing inflammation secondary to col-
orectal cancer and inflammatory bowel disease and its role in predicting AL has been
investigated. In one study of 100 colorectal anastomotic patients, in which 11 developed
an AL, faecal calprotectin levels were assessed 4 days after surgery. Results indicated that
faecal calprotectin was significantly higher (>300 µg/g) in patients who developed an AL
compared with those that recovered uneventfully (<90 µg/g). Faecal calprotectin levels
assessed in combination with CRP using a cut-off value of 120 mg/L provided a sensitivity
of 85%, specificity of 95% and an NPV of 95% for AL diagnosis [207].
Plasma markers of intestinal damage, such as liver, ileal bile acid and intestinal fatty
acid-binding proteins, have also been investigated as predictive AL biomarkers. Using a
pre-clinical intestinal resection and anastomosis rat model, post-operative serum intestinal
fatty acid-binding protein level was shown to be raised as early as the 3rd day following
surgery in those that developed an AL [208]. One human study demonstrated that pre-
operative intestinal fatty acid-binding protein levels >882 pg/mL had a sensitivity of
50% and specificity of 100% for predicting AL [167]. A further study demonstrated that
urinary intestinal fatty acid-binding protein and the urinary intestinal fatty acid-binding
protein:creatinine ratio on the 3rd day following colorectal surgery were significantly
elevated in patients with an AL. The authors suggested that this urine-based assay could
be used as a non-invasive assay for AL diagnosis [209].
11.4. Macrophage Biomarkers
Produced by macrophages, lysozyme is a substance which disrupts the cell wall of
Gram-negative bacteria. As lysozyme plays an important role in the inflammatory response
to sepsis and trauma, studies have begun investigating whether it could be used as an AL
biomarker. One study demonstrated that peritoneal lysozyme levels in patients on the 1st
day following a low anterior resection who had an uneventful post-operative recovery
were 5.5 mg/L. Significantly higher levels were seen in patients with clinical (180 mg/L)
and radiological (153 mg/L) evidence of AL [210]. Although the authors suggested that
lysozyme could be used for early AL diagnosis, the electrophoretic technique used had
significant practical restraints in terms of its usefulness as a rapid AL diagnostic test as the
gel required overnight soaking.
Neopterin, also produced by macrophages, is recognised as a biomarker of T helper cell
activation and plays a significant role in mediating inflammatory responses. Neopterin pro-
duction is stimulated by interferon-γ and can be detected in urine, cerebrospinal fluid and
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blood. Increased neopterin levels have been associated with viral, bacterial and parasitic
infections, autoimmune diseases, cancer [211], sepsis [212] and multiple organ dysfunc-
tion syndrome [213]. In terms of AL, one study has investigated pre- and post-operative
blood, urine and peritoneal fluid neopterin levels in colorectal resection and anastomosis
patients [214]. Results demonstrated that the pre-operative urinary neopterin:creatinine
ratio was significantly higher in patients that went on to develop an AL compared to those
that recovered uneventfully (139.5 µmol/mol vs. 114.8 µmol/mol). Patients that developed
complications also had higher urinary and peritoneal neopterin levels following surgery.
The authors suggested that high pre-operative levels of urinary neopterin could identify
AL high-risk patients and that monitoring post-operative urinary and peritoneal fluid
neopterin levels could be useful for early AL diagnosis.
11.5. Hyponatraemia
Hyponatremia, although a commonly diagnosed electrolyte disorder, has been pro-
posed as an inflammatory biomarker and a potential indicator of peritonitis [215]. Sodium
levels are predominantly maintained via osmotic vasopressin release mediated by intra-
vascular volume. However, research has shown potential immune-neuroendocrine path-
ways involving IL-6 which may have a role in non-osmotic driven vasopressin release
in response to inflammation [216,217]. Hyponatremia (<136 mmol/l) and leukocytosis
(>10 × 109/l) have subsequently been investigated as predictive AL biomarkers following
colorectal surgery [218]. Results from this study of 1025 patients identified that 23% (n = 19)
of AL patients and 15% (n = 69) of patients who recovered uneventfully had hyponatremia.
Leukocytosis was identified in 12 of the 19 patients with hyponatremia and an AL. Hy-
ponatraemia on the 5th day following surgery had a sensitivity of 23%, specificity of 93%,
NPV 97% and PPV of 5% for AL diagnosis. The combined presence of hyponatremia and
leukocytosis had a sensitivity of 68%, specificity of 75%, PPV of 18% and NPV of 97%.
The authors suggested that, due to low sensitivity (23%), hyponatremia absence cannot
exclude the presence of an AL. However, as the specificity of hyponatremia for an AL
was high, especially when it occurred in the presence of leucocytosis, this result should
raise suspicion of an AL being present. Further prospective trials are needed to confirm
these results.
12. Biomarkers of Tissue Repair
MMPs are a group of zinc-dependent endopeptidases that are involved with extracel-
lular matrix (ECM) remodelling. Secreted as an inactive pro-enzyme, they become active
following proteolytic cleavage [219]. Physiological and pathological processes involving
tissue repair and regeneration depend on the balance between MMP proteolysis and its
prevention by tissue inhibitors of metalloproteinase (TIMP) [220]. MMPs have been sug-
gested to play a role in AL development through inhibition of collagen synthesis. Although
collagen type I and III genes are normally overexpressed at anastomotic sites, in a rat model,
maximal gene expression was not reached until 7 days following surgery [221]. Further
animal models have demonstrated that colonic peri-anastomotic healing (as shown by
higher bursting pressures, improved structural layers and increased collagen production)
was improved through MMP inhibition [222–225]. Furthermore, human colonic tissue from
patients with poor anastomotic healing has demonstrated higher mucosal MMP-1 and
MMP-2 expression and higher submucosal MMP-2 and MMP-9 expression. Interestingly,
colonic samples from AL sites demonstrated a significantly lower collagen type I:III ratio
compared to uncomplicated anastomotic sites [226].
In a study of 58 colorectal anastomotic patients, peritoneal levels of MMP-1, 2, 3, 8 and
9 and TIMP-1 and 2 were assessed for 8 days following surgery. Differential levels of MMP
and TIMP were assessed on each day along with total MMP activity. Their levels were
shown to vary depending on the operation type and duration, amount of haemorrhage
and with the occurrence of post-operative complications. Only MMP-2 and MMP-9 levels
positively correlated with the development of post-operative complications, whereas
J. Pers. Med. 2021, 11, 471 16 of 29
TIMP-1 and TIMP-2 levels demonstrated a negative correlation. The authors suggested
that peritoneal MMP and TIMP may act as biomarkers of intestinal wound healing and
surgical outcome. However, as the patient cohort within the study was heterogeneous
and because the types of post-operative complications were not specified, further studies
are required [227]. In contrast to these results, a pilot study of 29 low anterior resection
patients had their peritoneal fluid levels of MMP-1, 2, 3, 7, 8, 9 and 13 assessed every 4 h
following surgery. Only MMP-8 and 9 were significantly increased in the 10 patients who
developed an AL compared with the 19 patients who had an uneventful post-operative
recovery [228].
In a recent systematic review, which included animal and human studies, the role of
tissue, blood and peritoneal MMP levels in the development of AL was investigated. The
results from 12 studies suggested that elevated MMP-9 levels were the most consistent
finding in patients that developed an AL [229]. The authors claimed that although these
studies suggested that tissue or peritoneal fluid levels of MMP and/or TIMP could act
as biomarkers for AL, the number of studies and number of patients used were small. In
addition, the inconsistent results for specific MMPs suggests that further investigations
are required.
13. The Intestinal Microbiome and Bacterial Contamination
The intestinal microbiome has been shown to play a role in the development of AL
and can be influenced by multiple peri-operative factors [71]. During intestinal surgery,
inadvertent spillage of intestinal contents can cause bacterial contamination of the ab-
dominal/pelvic cavities. In the majority of patients, immune responses deal with this
contamination and their post-operative recovery is not compromised. However, in patients
that develop anastomotic dehiscence, irrespective of its cause, significant and ongoing
bacterial contamination can overwhelm the patient’s immune system. A 5-year prospective
trial of patients diagnosed with abdominal sepsis syndrome (inflammatory response with
organ failure secondary to digestive tract perforation) identified multiple micro-organisms
to be present within their abdominal fluid. The peritoneal microbial flora composition
of these critically ill patients also varied depending on site of the intestinal perforation.
Following a colorectal perforation ~70% of intra-operative fluid samples contained aerobic
Gram-negative bacteria (Escherichia coli, Klebsiella and Pseudomonas species) whilst the
predominant anaerobic species was Bacteroides. Gram-positive bacteria (Enterococci and
Staphylococci) were found in ~50% of colorectal perforation cases. Antibiotic treatment
was also shown to change the microbial flora, causing Gram-negative bacterial counts to
drop whilst Gram-positive bacterial counts increased [230]. These results are supported by
another study which identified similar peritoneal microbial flora constituents following
intestinal perforation [231].
Bacterial Load
Assessment of peritoneal bacterial contamination has been investigated as an early
AL diagnostic biomarker. One study obtained post-operative peritoneal fluid samples for
microbial culture from 56 low anterior resection patients. In eight patients that had an AL
confirmed by imaging, Escherichia coli, Bacteroides, Klebsiella and Pseudomonas species were
identified on the 1st, 3rd and 5th days following surgery. Unfortunately, the specificity of
using culture results as an AL diagnostic test was low as several false positive cases occurred
in which all four bacterial species were identified in a patient without an AL [200]. The
clinical applicability and usefulness of peritoneal microbial cultures for rapid AL diagnosis
is also severely limited by the time required to grow laboratory cultures. To overcome this
issue, studies have investigated other techniques in which bacteria or bacterial components
can be identified.
In a pilot study of 17 colorectal anastomotic patients, a reverse transcription-polymerase
chain reaction (RT-PCR) assay designed to identify Escherichia coli and Enterococcus faecalis
was performed on 10 culture-positive and 7 culture-negative peritoneal fluid samples.
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While the RT-PCR results agreed with microbiological culture results, the assay suffered
from a lack of specificity, with four false positive results being identified. Although these
false positives all resulted from samples originating from a single patient with a surgical
site infection, the authors suggested that RT-PCR may be too sensitive for AL diagnosis,
leading to over-diagnosis and over-treatment [232]. To further investigate this, the authors
used the same Escherichia coli and Enterococcus faecalis RT-PCR assay in a multicentre study
involving 243 left-sided colonic anastomotic patients. In the 19 patients that developed a
symptomatic AL, Escherichia coli concentration was significantly increased on the 4th and
5th days following surgery, whereas Enterococcus faecalis was significantly increased on
days 2, 3 and 4. The authors suggested that Enterococcus faecalis on the 3rd day had the
highest diagnostic accuracy, with a sensitivity of 92.9% and NPV of 98.7% of AL diagnosis.
Although a number of false positives were still identified, the authors further suggested
that the absence of Enterococcus faecalis on day 3 could potentially exclude the presence of
an AL [233].
The use of online infrared absorption to spectroscopically detect bacteria in peritoneal
fluid samples has also been investigated as a means of identifying bacterial contamina-
tion. To provide proof-of-principle, one study demonstrated that this technique could
differentiate between peritoneal fluid samples obtained from a patient who recovered
uneventfully from those of a patient who developed post-operative complications with
highly contaminated peritoneal fluid. A significant increase in infrared absorption occurred
as contamination levels increased. The authors suggested that although the technique
cannot provide information on the source of the contamination, it has the potential to be
used as a bedside AL early-warning system [234]. Further studies are required to assess
the use of optical systems as AL diagnostic tools.
Peritoneal levels of endotoxins and lipopolysaccharide (LPS), which forms part of the
cell wall of Gram-negative bacteria (including intestinal commensals), have been suggested
as diagnostic biomarkers of peritonitis and AL [235]. One study measuring peritoneal LPS
levels from 22 colonic resection patients demonstrated significantly raised LPS levels on the
1st and 3rd days following surgery in three patients that developed an AL. Although LPS
differences between patients that recovered uneventfully and those that developed an AL
were great, standard deviations between patient groups were large. Two patients also had
surgery for perforated sigmoid diverticulitis, so elevated LPS levels may have been due
to pre-existing bacterial contamination [236]. Currently, LPS is not routinely measured in
clinical laboratories and further studies are required before its usability as an AL biomarker
can be determined.
14. Limitations of Biomarkers of Anastomotic Leakage and Future Perspectives
Biomarkers that can monitor intestinal healing, identify patients at high risk of devel-
oping an AL or provide early AL diagnosis, have the potential to significantly change how
we manage resection and anastomosis patients. Although pre-clinical and clinical research
continues to identify novel biomarkers for these purposes, none have made it into clinical
use. Stumbling blocks for the translation of study results into practice changing policies is
complicated but can be related to study design and the usability of the assay itself.
Direct comparison between biomarker studies is difficult, not only because many
use heterogeneous patient populations, but also because of a lack of a single, clearly
defined AL definition. Some studies use asymptomatic patients with diagnosis based on
imaging, whilst others only use patients exhibiting clinical signs. These clinical signs can
also be wide-ranging, from non-specific to the presence of a faecal fistula or multi-organ
failure. A significant number of studies are also retrospective in nature. Although this
means large sample sizes can be obtained, studies can run for several years, over which
time the surgical team, surgical techniques and post-operative management practices can
change significantly. Studies also differ in the timings of blood tests and/or peritoneal
fluid analysis, with biomarker levels rarely evaluated specifically in terms of anastomotic
position (colonic and rectal resections) or the underlying disease process. They also fail
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to account for medications or treatments that may alter inflammatory responses, such as
statins, steroids, chemotherapy or radiotherapy. All these considerations are especially
important when AL cut-off values are determined from study results; these differences will
undoubtably have contributed to the significant variations in AL cut-off values reported
across these studies. Standardised, multicentre prospective studies are needed to overcome
these issues.
A large number of studies suggest that peritoneal fluid samples obtained from ab-
dominal drains provide a better indication of the peri-anastamotic tissue environment
than blood samples. Although this may be true, studies typically fail to document drain
location and type, which makes comparing results from different studies challenging. It has
also been shown that drain location can influence drain fluid composition [237]. As gross
body movements, including coughing, can affect drain location, this means that changes
in drain fluid biomarker levels may be solely due to changes in drain location rather than
fluctuations in patient status or intestinal healing. The clinical value of using peritoneal
drains after a resection and anastomosis also remains a contentious issue. Several studies
and meta-analyses have not shown any benefit of peritoneal drainage in decreasing AL
incidence [238–240]. If surgeons are unwilling to routinely place them at surgery, then
basing a biomarker assay on drain fluid will ultimately fail to reach clinical use. Strong
clinical evidence proving that peritoneal drain fluid analysis is useful for the management
of these patients is needed to allow peritoneal drainage to become routine and no longer
controversial.
In terms of developing a clinically usable assay, certain biomarkers have inherent
problems. Biomarkers such as cytokines and MMP are labile, meaning that peritoneal fluid
analysis has to be performed immediately. Expensive and labour-intensive assays such
as enzyme-linked immunosorbent assays (ELISA) or PCR technologies also have clinical
limitations as laboratory processing, even if available in the hospital, incurs inherent time
delays in reporting results. Studies that have investigated bacterial contamination have
also shown a lack of clinical usability, either through time delays associated with growing
cultures or through high false positive rates with RT-PCR assays.
Researchers are continuing to investigate methods to overcome these issues. Multidis-
ciplinary projects involving engineers, chemists and clinicians are looking at ways in which
implantable medical devices and sensor technologies could be utilised for such purposes.
Studies such as the IMPACT project have already provided initial results regarding the
development of miniaturised O2 and pH sensors. Further research will undoubtably lead
into the creation of sensors for the detection of the most promising AL biomarkers, such
as CRP, lactate and pyruvate (Figure 2). Wireless technology also creates the possibility
of producing a biodegradable implant, which could be fixed around the anastomosis to
remotely provide information about the tissue environment. Although this research is still
in its infancy, technological advancements may ultimately deliver a simple, acceptable
and low-cost method of measuring known AL biomarkers from peritoneal fluid directly
surrounding an anastomosis or from peri-anastamotic serosal surfaces on which the sensors
are placed.
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in the identification of diagnostic and predictive biomarkers of AL. This research is driven 
by the clinical need to identify patients at high risk of developing an AL and to diagnose 
AL earlier than current protocols allow. The ideal biomarker would allow for rapid, cost-
effective and reliable prediction or detection of an AL in a time frame that allows clinicians 
to instigate interventions that minimise patient morbidity and mortality. Here, we have 
highlighted the current, most promising potential candidate biomarkers, including 
ischaemic metabolites, inflammatory markers and bacterial components. Although none 
of these biomarkers have yet been validated in large-scale clinical trials, with none in 
routine clinical use, ongoing biomarker research in the field of intestinal surgery holds 
much promise. The incorporation of such biomarkers outlined in our review with other 
techniques, such as clinical status, routine haematological and biochemical analysis and 
imaging, has the potential to deliver an overall precision medicine package that could 
significantly enhance the effectiveness of a patient’s post-operative care. There is a need, 
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15. Conclusions
In the field of colorectal cancer research, significant advancements have been made in
the identification of diagnostic and predictive biomarkers of AL. This research is driven
by the clinical need to identify patients at high risk of developing an AL and to diagnose
AL earlier than current protocols allow. The ideal biomarker would allow for rapid,
cost-effective and reliable prediction or detection of an AL in a time frame that allows
clinicians to instigate interventions that minimise patient morbidity and mortality. Here,
we have highlighted the current, most promising potential candidate biomarkers, including
ischaemic metabolites, inflam atory markers and bacterial components. Although none
of t ese b omarkers have yet been validated in large-scale clinical trials, with none in
routine clini al use, ongoing bi marker research in the field of ntestinal urgery holds
uch promise. Th incorporation of such biomarkers outli ed in our review with other
techniques, such as clinical status, routine haematological and biochemical analysis and
imaging, has the potential to deliver an overall precision medicine package that could
significantly enhance the effectiveness of a patient’s post-operative care. There is a need,
now more than ever, to utilise our knowledge of these biomarkers in carefully designed
prospective, multicentre studies. These trials should be designed to investigate whether
proactive post-operative patient management based on predictive biomarker levels can be
used to reduce AL rates. There is confidence within the scientific community that precision
medicine, through the incorporation of biomarker analysis, will finally be realised for
intestinal r section and anastomosis patients in the decades to come.
Author Contributions: M.A.P., D.J.A. and A.F.M. secured funding for this research. M.G. wrote the
majority of the manuscript and composed the figures, with significant contributions from J.R.K.M.
Critical revisions were made by M.G., J.R.K.M., A.F.M., D.J.A. and M.A.P. All authors have read and
agreed to the published version of the manuscript.
Funding: This research was funded by the UK Engineering and Physical Sciences Research Coun-
cil, through the IMPACT programme grant (EP/K-34510/1), and a project grant from Bowel and
Cancer Research.
Institutional Review Board Statement: Not applicable.
J. Pers. Med. 2021, 11, 471 20 of 29
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of
incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [CrossRef]
2. Cancer Research UK. Cancer Statistics for the UK. Available online: www.cancerresearchuk.org (accessed on 12 March 2021).
3. Peel, A.L.; Taylor, E.W. Proposed definitions for the audit of postoperative infection: A discussion paper. Surgical Infection Study
Group. Ann. R. Coll. Surg. Engl. 1991, 73, 385–388.
4. Bruce, J.; Krukowski, Z.H.; Al-Khairy, G.; Russell, E.M.; Park, K.G.M. Systematic review of the definition and measurement of
anastomotic leak after gastrointestinal surgery. BJS 2002, 88, 1157–1168. [CrossRef] [PubMed]
5. Rahbari, N.N.; Weitz, J.; Hohenberger, W.; Heald, R.J.; Moran, B.; Ulrich, A.; Holm, T.; Wong, W.D.; Tiret, E.; Moriya, Y.; et al.
Definition and grading of anastomotic leakage following anterior resection of the rectum: A proposal by the International Study
Group of Rectal Cancer. Surgery 2010, 147, 339–351. [CrossRef] [PubMed]
6. Kulu, Y.; Ulrich, A.; Bruckner, T.; Contin, P.; Welsch, T.; Rahbari, N.N.; Büchler, M.W.; Weitz, J. Validation of the International
Study Group of Rectal Cancer definition and severity grading of anastomotic leakage. Surgery 2013, 153, 753–761. [CrossRef]
7. Hyman, N.; Manchester, T.L.; Osler, T.; Burns, B.; Cataldo, P.A. Anastomotic Leaks after Intestinal Anastomosis: It’s Later than
You Think. Ann. Surg. 2007, 245, 254–258. [CrossRef]
8. Boccola, M.A.; Buettner, P.G.; Rozen, W.M.; Siu, S.K.; Stevenson, A.R.L.; Stitz, R.; Ho, Y.-H. Risk Factors and Outcomes for
Anastomotic Leakage in Colorectal Surgery: A Single-Institution Analysis of 1576 Patients. World J. Surg. 2011, 35, 186–195.
[CrossRef] [PubMed]
9. Kingham, T.P.; Pachter, H.L. Colonic Anastomotic Leak: Risk Factors, Diagnosis, and Treatment. J. Am. Coll. Surg. 2009, 208,
269–278. [CrossRef]
10. Hallböök, O.; Sjödahl, R. Anastomotic leakage and functional outcome after anterior resection of the rectum. BJS 1996, 83, 60–62.
[CrossRef]
11. Kube, R.; Mroczkowski, P.; Granowski, D.; Benedix, F.; Sahm, M.; Schmidt, U.; Gastinger, I.; Lippert, H. Anastomotic leakage after
colon cancer surgery: A predictor of significant morbidity and hospital mortality, and diminished tumour-free survival. Eur. J.
Surg. Oncol. 2010, 36, 120–124. [CrossRef]
12. Marra, F.; Steffen, T.; Kalak, N.; Warschkow, R.; Tarantino, I.; Lange, J.; Zünd, M. Anastomotic leakage as a risk factor for the
long-term outcome after curative resection of colon cancer. Eur. J. Surg. Oncol. 2009, 35, 1060–1064. [CrossRef] [PubMed]
13. Dulk, M.D.; Noter, S.; Hendriks, E.; Brouwers, M.; van der Vlies, C.; Oostenbroek, R.; Menon, A.; Steup, W.; van de Velde,
C. Improved diagnosis and treatment of anastomotic leakage after colorectal surgery. Eur. J. Surg. Oncol. 2009, 35, 420–426.
[CrossRef] [PubMed]
14. Bell, S.W.; Walker, K.G.; Rickard, M.J.F.X.; Sinclair, G.; Dent, O.F.; Chapuis, P.H.; Bokey, E.L. Anastomotic leakage after curative
anterior resection results in a higher prevalence of local recurrence. BJS 2003, 90, 1261–1266. [CrossRef]
15. Petersen, S.; Freitag, M.; Hellmich, G.; Ludwig, K. Anastomotic leakage: Impact on local recurrence and survival in surgery of
colorectal cancer. Int. J. Colorectal Dis. 1998, 13, 160–163. [CrossRef] [PubMed]
16. Branagan, G.; Finnis, D. Prognosis after Anastomotic Leakage in Colorectal Surgery. Dis. Colon Rectum 2005, 48, 1021–1026.
[CrossRef]
17. Wang, S.; Liu, J.; Wang, S.; Zhao, H.; Ge, S.; Wang, W. Adverse Effects of Anastomotic Leakage on Local Recurrence and Survival
After Curative Anterior Resection for Rectal Cancer: A Systematic Review and Meta-analysis. World J. Surg. 2016, 41, 277–284.
[CrossRef]
18. Ramphal, W.; Boeding, J.R.; Gobardhan, P.D.; Rutten, H.J.; de Winter, L.J.B.; Crolla, R.M.; Schreinemakers, J.M. Oncologic outcome
and recurrence rate following anastomotic leakage after curative resection for colorectal cancer. Surg. Oncol. 2018, 27, 730–736.
[CrossRef]
19. Umpleby, H.C.; Fermor, B.; Symes, M.O.; Williamson, R.C.N. Viability of exfoliated colorectal carcinoma cells. BJS 2005, 71,
659–663. [CrossRef]
20. Symes, M.O.; Fermor, B.; Umpleby, H.C.; Tribe, C.R.; Williamson, R.C. Cells exfoliated from colorectal cancers can proliferate in
immune deprived mice. Br. J. Cancer 1984, 50, 423–425. [CrossRef]
21. Fermor, B.; Umpleby, H.C.; Lever, J.V.; Symes, M.O.; Williamson, R.C.N. Proliferative and Metastatic Potential of Exfoliated
Colorectal Cancer Cells. J. Natl. Cancer Inst. 1986, 76, 347–349. [CrossRef] [PubMed]
22. Gertsch, P.; Baer, H.U.; Kraft, R.; Maddern, G.J.; Altermatt, H.J. Malignant cells are collected on circular staplers. Dis. Colon
Rectum 1992, 35, 238–241. [CrossRef] [PubMed]
23. Tol, P.M.V.D.; Van Rossen, E.E.M.; Van Eijck, C.H.J.; Bonthuis, F.; Marquet, R.L.; Jeekel, H. Reduction of Peritoneal Trauma By
Using Nonsurgical Gauze Leads to Less Implantation Metastasis of Spilled Tumor Cells. Ann. Surg. 1998, 227, 242–248. [CrossRef]
[PubMed]
J. Pers. Med. 2021, 11, 471 21 of 29
24. Skipper, D.; Cooper, A.J.; Marston, J.E.; Taylor, I. Exfoliated cells and in vitro growth in colorectal cancer. BJS 1987, 74, 1049–1052.
[CrossRef]
25. Baskaranathan, S.; Philips, J.; McCredden, P.; Solomon, M. Free Colorectal Cancer Cells on the Peritoneal Surface: Correlation
with Pathologic Variables and Survival. Dis. Colon Rectum 2004, 47, 2076–2079. [CrossRef] [PubMed]
26. Aggarwal, B.B.; Vijayalekshmi, R.V.; Sung, B. Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term
Friend, Long-Term Foe. Clin. Cancer Res. 2009, 15, 425–430. [CrossRef]
27. Wu, Y.; Zhou, B.P. Inflammation: A driving force speeds cancer metastasis. Cell Cycle 2009, 8, 3267–3273. [CrossRef]
28. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature 2008, 454, 436–444. [CrossRef] [PubMed]
29. Karin, M. Nuclear factor-κB in cancer development and progression. Nature 2006, 441, 431–436. [CrossRef] [PubMed]
30. Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature 2002, 420, 860–867. [CrossRef] [PubMed]
31. McMillan, D.C.; Canna, K.; McArdle, C.S. Systemic inflammatory response predicts survival following curative resection of
colorectal cancer. BJS 2003, 90, 215–219. [CrossRef] [PubMed]
32. Canna, K.; McMillan, D.C.; McKee, R.F.; McNicol, A.-M.; Horgan, P.G.; McArdle, C.S. Evaluation of a cumulative prognostic score
based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer. Br. J.
Cancer 2004, 90, 1707–1709. [CrossRef] [PubMed]
33. Bohle, B.; Pera, M.; Pascual, M.; Alonso, S.; Mayol, X.; Salvado, M.; Schmidt, J.; Grande, L. Postoperative intra-abdominal infection
increases angiogenesis and tumor recurrence after surgical excision of colon cancer in mice. Surgery 2010, 147, 120–126. [CrossRef]
[PubMed]
34. Lindgren, R.; Hallböök, O.; Rutegård, J.; Sjödahl, R.; Matthiessen, P. What Is the Risk for a Permanent Stoma After Low Anterior
Resection of the Rectum for Cancer? A Six-Year Follow-Up of a Multicenter Trial. Dis. Colon Rectum 2011, 54, 41–47. [CrossRef]
[PubMed]
35. Choi, H.-K.; Law, W.-L.; Ho, J.W.C. Leakage after Resection and Intraperitoneal Anastomosis for Colorectal Malignancy: Analysis
of Risk Factors. Dis. Colon Rectum 2006, 49, 1719–1725. [CrossRef]
36. La Regina, D.; Di Giuseppe, M.; Lucchelli, M.; Saporito, A.; Boni, L.; Efthymiou, C.; Cafarotti, S.; Marengo, M.; Mongelli, F.
Financial Impact of Anastomotic Leakage in Colorectal Surgery. J. Gastrointest. Surg. 2018, 23, 580–586. [CrossRef]
37. Brisinda, G.; Vanella, S.; Cadeddu, F.; Civello, I.M.; Brandara, F.; Nigro, C.; Mazzeo, P.; Marniga, G.; Maria, G. End-to-end versus
end-to-side stapled anastomoses after anterior resection for rectal cancer. J. Surg. Oncol. 2009, 99, 75–79. [CrossRef]
38. Koperna, T. Cost-effectiveness of defunctioning stomas in low anterior resections for rectal cancer: A call for benchmarking. Arch.
Surg. 2003, 138, 1334–1338. [CrossRef]
39. Ashraf, S.; Burns, E.; Jani, A.; Altman, S.; Young, J.; Cunningham, C.; Faiz, O.; Mortensen, N. The economic impact of anastomotic
leakage after anterior resections in English NHS hospitals: Are we adequately remunerating them? Colorectal Dis. 2013, 15,
e190–e198. [CrossRef]
40. Nesbakken, A.; Nygaard, K.; Lunde, O.C. Outcome and late functional results after anastomotic leakage following mesorectal
excision for rectal cancer. BJS 2002, 88, 400–404. [CrossRef]
41. Hammond, J.; Lim, S.; Wan, Y.; Gao, X.; Patkar, A. The Burden of Gastrointestinal Anastomotic Leaks: An Evaluation of Clinical
and Economic Outcomes. J. Gastrointest. Surg. 2014, 18, 1176–1185. [CrossRef]
42. Murrell, Z.A.; Stamos, M.J. Reoperation for Anastomotic Failure. Clin. Colon Rectal Surg. 2006, 19, 213–216. [CrossRef] [PubMed]
43. Macarthur, D.C.; Nixon, S.J.; Aitken, R.J. Avoidable deaths still occur after large bowel surgery. BJS 2003, 85, 80–83. [CrossRef]
[PubMed]
44. Alves, A.; Panis, Y.; Pocard, M.; Regimbeau, J.-M.; Valleur, P. Management of anastomotic leakage after nondiverted large bowel
resection. J. Am. Coll. Surg. 1999, 189, 554–559. [CrossRef]
45. Alves, Y.P.A.; Panis, Y.; Trancart, D.; Regimbeau, J.-M.; Pocard, M.; Valleur, P. Factors Associated with Clinically Significant
Anastomotic Leakage after Large Bowel Resection: Multivariate Analysis of 707 Patients. World J. Surg. 2002, 26, 499–502.
[CrossRef]
46. Dellinger, R.P.; The Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup; Levy, M.M.; Rhodes, A.;
Annane, D.; Gerlach, H.; Opal, S.M.; Sevransky, J.E.; Sprung, C.L.; Douglas, I.S.; et al. Surviving Sepsis Campaign: International
Guidelines for Management of Severe Sepsis and Septic Shock, 2012. Intensive Care Med. 2013, 39, 165–228. [CrossRef]
47. Lundy, J.B. A Primer on Wound Healing in Colorectal Surgery in the Age of Bioprosthetic Materials. Clin. Colon Rectal Surg. 2014,
27, 125–133. [CrossRef]
48. Thompson, S.K.; Chang, E.Y.; Jobe, B.A. Clinical review: Healing in gastrointestinal anastomoses, Part I. Microsurgery 2006, 26,
131–136. [CrossRef]
49. Enestvedt, C.K.; Thompson, S.K.; Chang, E.Y.; Jobe, B.A. Clinical review: Healing in gastrointestinal anastomoses, Part II.
Microsurgery 2006, 26, 137–143. [CrossRef]
50. Trencheva, K.; Morrissey, K.P.; Wells, M.; Mancuso, C.A.; Lee, S.W.; Sonoda, T.; Michelassi, F.; Charlson, M.E.; Milsom, J.W.
Identifying important predictors for anastomotic leak after colon and rectal resection: Prospective study on 616 patients. Ann.
Surg. 2013, 257, 108–113. [CrossRef]
51. Park, J.S.; Choi, G.-S.; Kim, S.H.; Kim, H.R.; Kim, N.K.; Lee, K.Y.; Kang, S.B.; Kim, J.Y.; Lee, K.Y.; Kim, B.C. Multicenter analysis of
risk factors for anastomotic leakage after laparoscopic rectal cancer excision: The Korean laparoscopic colorectal surgery study
group. Ann. Surg. 2013, 257, 665–671. [CrossRef]
J. Pers. Med. 2021, 11, 471 22 of 29
52. Jung, S.H.; Yu, C.S.; Choi, P.W.; Kim, D.D.; Park, I.J.; Kim, H.C.; Kim, J.C. Risk Factors and Oncologic Impact of Anastomotic
Leakage after Rectal Cancer Surgery. Dis. Colon Rectum 2008, 51, 902–908. [CrossRef]
53. Law, W.-L.; Chu, K.-W.; Ho, J.W.; Chan, C.-W. Risk factors for anastomotic leakage after low anterior resection with total
mesorectal excision. Am. J. Surg. 2000, 179, 92–96. [CrossRef]
54. Ba, Z.F.; Yokoyama, Y.; Toth, B.; Rue, L.W.; Bland, K.I.; Chaudry, I.H. Gender differences in small intestinal endothelial function:
Inhibitory role of androgens. Am. J. Physiol. Liver Physiol. 2004, 286, G452–G457. [CrossRef] [PubMed]
55. Bakker, I.S.; Grossmann, I.; Henneman, D.; Havenga, K.; Wiggers, T. Risk factors for anastomotic leakage and leak-related
mortality after colonic cancer surgery in a nationwide audit. BJS 2014, 101, 424–432. [CrossRef] [PubMed]
56. Buchs, N.C.; Gervaz, P.; Secic, M.; Bucher, P.; Mugnier-Konrad, B.; Morel, P. Incidence, consequences, and risk factors for
anastomotic dehiscence after colorectal surgery: A prospective monocentric study. Int. J. Colorectal Dis. 2008, 23, 265–270.
[CrossRef]
57. Kwag, S.-J.; Kim, J.-G.; Kang, W.-K.; Lee, J.-K.; Oh, S.-T. The nutritional risk is a independent factor for postoperative morbidity in
surgery for colorectal cancer. Ann. Surg. Treat. Res. 2014, 86, 206–211. [CrossRef] [PubMed]
58. Veyrie, N.; Ata, T.; Muscari, F.; Couchard, A.-C.; Msika, S.; Hay, J.-M.; Fingerhut, A.; Dziri, C. Anastomotic Leakage after Elective
Right Versus Left Colectomy for Cancer: Prevalence and Independent Risk Factors. J. Am. Coll. Surg. 2007, 205, 785–793.
[CrossRef]
59. Kang, C.Y.; Halabi, W.J.; Chaudhry, O.O.; Nguyen, V.; Pigazzi, A.; Carmichael, J.; Mills, S.; Stamos, M.J. Risk Factors for
Anastomotic Leakage After Anterior Resection for Rectal Cancer. JAMA Surg. 2013, 148, 65–71. [CrossRef]
60. Hennessey, D.B.; Burke, J.P.; Ni-Dhonochu, T.; Shields, C.; Winter, D.C.; Mealy, K. Preoperative hypoalbuminemia is an
independent risk factor for the development of surgical site infection following gastrointestinal surgery: A multi-institutional
study. Ann. Surg. 2010, 252, 325–329. [CrossRef]
61. Hayden, D.M.; Pinzon, M.C.M.; Francescatti, A.B.; Saclarides, T.J. Patient factors may predict anastomotic complications after
rectal cancer surgery: Anastomotic complications in rectal cancer. Ann. Med. Surg. 2015, 4, 11–16. [CrossRef]
62. Tibbs, M.K. Wound healing following radiation therapy: A review. Radiother. Oncol. 1997, 42, 99–106. [CrossRef]
63. Hu, M.-H.; Huang, R.-K.; Zhao, R.-S.; Yang, K.-L.; Wang, H. Does neoadjuvant therapy increase the incidence of anastomotic
leakage after anterior resection for mid and low rectal cancer? A systematic review and meta-analysis. Colorectal Dis. 2017, 19,
16–26. [CrossRef] [PubMed]
64. Pommergaard, H.-C.; Gessler, B.; Burcharth, J.; Angenete, E.; Haglind, E.; Rosenberg, J. Preoperative risk factors for anastomotic
leakage after resection for colorectal cancer: A systematic review and meta-analysis. Colorectal Dis. 2014, 16, 662–671. [CrossRef]
65. Sciuto, A.; Merola, G.; De Palma, G.D.; Sodo, M.; Pirozzi, F.; Bracale, U.M. Predictive factors for anastomotic leakage after
laparoscopic colorectal surgery. World J. Gastroenterol. 2018, 24, 2247–2260. [CrossRef] [PubMed]
66. Volk, A.; Kersting, S.; Held, H.C.; Saeger, H.D. Risk factors for morbidity and mortality after single-layer continuous suture for
ileocolonic anastomosis. Int. J. Colorectal Dis. 2010, 26, 321–327. [CrossRef] [PubMed]
67. Ziegler, M.A.; Catto, J.A.; Riggs, T.W.; Gates, E.R.; Grodsky, M.B.; Wasvary, H.J. Risk factors for anastomotic leak and mortality in
diabetic patients undergoing colectomy: Analysis from a statewide surgical quality collaborative. Arch. Surg. 2012, 147, 600–605.
[CrossRef]
68. Richards, C.H.; Campbell, V.; Ho, C.; Hayes, J.; Elliott, T.; Thompson-Fawcett, M. Smoking is a major risk factor for anastomotic
leak in patients undergoing low anterior resection. Colorectal Dis. 2011, 14, 628–633. [CrossRef]
69. Biondo, S.; Parés, D.; Kreisler, E.; Ragué, J.M.; Fraccalvieri, D.; Ruiz, A.G.; Jaurrieta, E. Anastomotic Dehiscence After Resection
and Primary Anastomosis in Left-Sided Colonic Emergencies. Dis. Colon Rectum 2005, 48, 2272–2280. [CrossRef]
70. Sørensen, L.T.; Jørgensen, T.; Kirkeby, L.T.; Skovdal, J.; Vennits, B.; Wille-Jørgensen, P. Smoking and alcohol abuse are major risk
factors for anastomotic leakage in colorectal surgery. BJS 2002, 86, 927–931. [CrossRef]
71. Gershuni, V.M.; Friedman, E.S. The Microbiome-Host Interaction as a Potential Driver of Anastomotic Leak. Curr. Gastroenterol.
Rep. 2019, 21, 4. [CrossRef]
72. Schardey, H.M.; Kamps, T.; Rau, H.G.; Gatermann, S.; Baretton, G.; Schildberg, F.W. Bacteria: A major pathogenic factor for
anastomotic insufficiency. Antimicrob. Agents Chemother. 1994, 38, 2564–2567. [CrossRef]
73. Schardey, H.M.; Joosten, U.; Finke, U.; Staubach, K.H.; Schauer, R.; Heiss, A.; Kooistra, A.; Rau, H.G.; Nibler, R.; Lüdeling, S.;
et al. The Prevention of Anastomotic Leakage after Total Gastrectomy with Local Decontamination. A prospective, randomized,
double-blind, placebo-controlled multicenter trial. Ann. Surg. 1997, 225, 172–180. [CrossRef]
74. Shogan, B.D.; Carlisle, E.M.; Alverdy, J.C.; Umanskiy, K. Do We Really Know Why Colorectal Anastomoses Leak? J. Gastrointest.
Surg. 2013, 17, 1698–1707. [CrossRef]
75. Shogan, B.D.; Belogortseva, N.; Luong, P.M.; Zaborin, A.; Lax, S.; Bethel, C.; Ward, M.; Muldoon, J.P.; Singer, M.; An, G. Collagen
degradation and MMP9 activation by Enterococcus faecalis contribute to intestinal anastomotic leak. Sci. Transl. Med. 2015,
7, 286ra68. [CrossRef]
76. Øines, M.N.; Krarup, P.-M.; Jorgensen, L.N.; Ågren, M.S. Pharmacological interventions for improved colonic anastomotic
healing: A meta-analysis. World J. Gastroenterol. 2014, 20, 12637–12648. [CrossRef]
77. Damen, N.; Spilsbury, K.; Levitt, M.; Makin, G.; Salama, P.; Tan, P.; Penter, C.; Platell, C. Anastomotic leaks in colorectal surgery.
ANZ J. Surg. 2014, 84, 763–768. [CrossRef]
J. Pers. Med. 2021, 11, 471 23 of 29
78. McDermott, F.D.; Heeney, A.; Kelly, M.E.; Steele, R.J.; Carlson, G.L.; Winter, D.C. Systematic review of preoperative, intraoperative
and postoperative risk factors for colorectal anastomotic leaks. BJS 2015, 102, 462–479. [CrossRef]
79. Akiyoshi, T.; Ueno, M.; Fukunaga, Y.; Nagayama, S.; Fujimoto, Y.; Konishi, T.; Kuroyanagi, H.; Yamaguchi, T. Incidence of and risk
factors for anastomotic leakage after laparoscopic anterior resection with intracorporeal rectal transection and double-stapling
technique anastomosis for rectal cancer. Am. J. Surg. 2011, 202, 259–264. [CrossRef]
80. Tortorelli, A.P.; Alfieri, S.; Sanchez, A.M.; Rosa, F.; Papa, V.; Di Miceli, D.; Bellantone, C.; Doglietto, G.B. Anastomotic Leakage
after Anterior Resection for Rectal Cancer with Mesorectal Excision: Incidence, Risk Factors, and Management. Am. Surg. 2015,
81, 41–47. [CrossRef]
81. Naumann, D.N.; Bhangu, A.; Kelly, M.; Bowley, D.M. Stapled versus handsewn intestinal anastomosis in emergency laparotomy:
A systemic review and meta-analysis. Surgery 2015, 157, 609–618. [CrossRef]
82. Slesser, A.A.P.; Pellino, G.; Shariq, O.; Cocker, D.; Kontovounisios, C.; Rasheed, S.; Tekkis, P.P. Compression versus hand-sewn
and stapled anastomosis in colorectal surgery: A systematic review and meta-analysis of randomized controlled trials. Tech.
Coloproctol. 2016, 20, 667–676. [CrossRef]
83. Jayne, D.G.; Thorpe, H.C.; Copeland, J.; Quirke, P.; Brown, J.M.; Guillou, P.J. Five-year follow-up of the Medical Research
Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. BJS 2010, 97, 1638–1645. [CrossRef]
[PubMed]
84. Vasiliu, E.C.Z.; Zarnescu, N.O.; Costea, R.; Neagu, S. Review of Risk Factors for Anastomotic Leakage in Colorectal Surgery. Chir.
2015, 110, 319.
85. Vennix, S.; Pelzers, L.; Bouvy, N.; Beets, G.L.; Pierie, J.-P.; Wiggers, T.; Breukink, S. Laparoscopic versus open total mesorectal
excision for rectal cancer. Cochrane Database Syst. Rev. 2014, 4, CD005200. [CrossRef] [PubMed]
86. Kim, N.-K.; Kang, J. Optimal total mesorectal excision for rectal cancer: The role of robotic surgery from an expert’s view. J.
Korean Soc. Coloproctol 2010, 26, 377. [CrossRef] [PubMed]
87. Cho, M.S.; Baek, S.J.; Hur, H.; Min, B.S.; Baik, S.H.; Lee, K.Y.; Kim, N.K. Short and long-term outcomes of robotic versus
laparoscopic total mesorectal excision for rectal cancer: A case-matched retrospective study. Medicine 2015, 94, e522. [CrossRef]
88. Lim, D.R.; Bae, S.U.; Hur, H.; Min, B.S.; Baik, S.H.; Lee, K.Y.; Kim, N.K. Long-term oncological outcomes of robotic versus
laparoscopic total mesorectal excision of mid–low rectal cancer following neoadjuvant chemoradiation therapy. Surg. Endosc.
2016, 31, 1728–1737. [CrossRef]
89. Smith, J.A.E.; King, P.M.; Lane, R.H.S.; Thompson, M.R. Evidence of the effect of ‘specialization’ on the management, surgical
outcome and survival from colorectal cancer in Wessex. BJS 2003, 90, 583–592. [CrossRef]
90. Singh, K.K.; Aitken, R.J. Outcome in patients with colorectal cancer managed by surgical trainees. BJS 2002, 86, 1332–1336.
[CrossRef]
91. Fujiwata, H.; Kuga, T.; Esato, K. High submucosal blood flow and low anastomotic tension prevent anastomotic leakage in
rabbits. Surg. Today 1997, 27, 924–929. [CrossRef] [PubMed]
92. Attard, J.-A.P.; Raval, M.J.; Martin, G.R.; Kolb, J.; Afrouzian, M.; Buie, D.W.; Sigalet, D.L. The Effects of Systemic Hypoxia on
Colon Anastomotic Healing: An Animal Model. Dis. Colon Rectum 2005, 48, 1460–1470. [CrossRef] [PubMed]
93. Sheridan, W.G.; Lowndes, R.H.; Young, H.L. Tissue oxygen tension as a predictor of colonic anastomotic healing. Dis. Colon
Rectum 1987, 30, 867–871. [CrossRef] [PubMed]
94. Khan, A.A.; Wheeler, J.M.D.; Cunningham, C.; George, B.; Kettlewell, M.; Mortensen, N.J.M. The management and outcome of
anastomotic leaks in colorectal surgery. Colorectal Dis. 2008, 10, 587–592. [CrossRef] [PubMed]
95. Sutton, C.D.; Marshall, L.J.; Williams, N.; Berry, D.P.; Thomas, W.M.; Kelly, M.J. Colo-rectal anastomotic leakage often masquerades
as a cardiac complication. Colorectal Dis. 2003, 6, 21–22. [CrossRef]
96. Karliczek, A.; Harlaar, N.J.; Zeebregts, C.J.; Wiggers, T.; Baas, P.C.; Van Dam, G.M. Surgeons lack predictive accuracy for
anastomotic leakage in gastrointestinal surgery. Int. J. Colorectal Dis. 2009, 24, 569–576. [CrossRef]
97. Liu, Y.; Wan, X.; Wang, G.; Ren, Y.; Cheng, Y.; Zhao, Y.; Han, G. A scoring system to predict the risk of anastomotic leakage after
anterior resection for rectal cancer. J. Surg. Oncol. 2014, 109, 122–125. [CrossRef]
98. Dekker, J.W.T.; Liefers, G.J.; Otterloo, J.C.D.M.V.; Putter, H.; Tollenaar, R.A. Predicting the Risk of Anastomotic Leakage in
Left-sided Colorectal Surgery Using a Colon Leakage Score. J. Surg. Res. 2011, 166, e27–e34. [CrossRef]
99. Martin, G.; Dupré, A.; Mulliez, A.; Prunel, F.; Slim, K.; Pezet, D. Validation of a score for the early diagnosis of anastomotic
leakage following elective colorectal surgery. J. Visc. Surg. 2015, 152, 5–10. [CrossRef]
100. Dulk, M.D.; Witvliet, M.J.; Kortram, K.; Neijenhuis, P.A.; De Hingh, I.H.; Engel, A.F.; Van De Velde, C.J.; De Brauw, L.M.; Putter,
H.; Brouwers, M.A.; et al. The DULK (Dutch leakage) and modified DULK score compared: Actively seek the leak. Colorectal Dis.
2013, 15, e528–e533. [CrossRef]
101. Khoury, W.; Ben-Yehuda, A.; Ben-Haim, M.; Klausner, J.M.; Szold, O. Abdominal Computed Tomography for Diagnosing
Postoperative Lower Gastrointestinal Tract Leaks. J. Gastrointest. Surg. 2009, 13, 1454–1458. [CrossRef]
102. Nesbakken, A.; Nygaard, K.; Lunde, O.C.; Blucher, J.; Gjertsen, O.; Dullerud, R. Anastomotic leak following mesorectal excision
for rectal cancer: True incidence and diagnostic challenges. Colorectal Dis. 2005, 7, 576–581. [CrossRef]
103. Gollgher, J.; Graham, N.; de Dombal, F. Anastomotic dehiscence after anterior resection of rectum and sigmold. Br. J. Surg. 1970,
57, 109–118. [CrossRef]
J. Pers. Med. 2021, 11, 471 24 of 29
104. Tang, C.-L.; Seow-Choen, F. Digital rectal examination compares favourably with conventional water-soluble contrast enema in
the assessment of anastomotic healing after low rectal excision: A cohort study. Int. J. Colorectal Dis. 2004, 20, 262–266. [CrossRef]
105. Williams, C.E.; Makin, C.A.; Reeve, R.G.; Ellenbogen, S.B. Over-utilisation of radiography in the assessment of stapled colonic
anastomoses. Eur. J. Radiol. 1991, 12, 35–37. [CrossRef]
106. Akyol, A.M.; McGregor, J.R.; Galloway, D.J.; George, W.D. Early postoperative contrast radiology in the assessment of colorectal
anastomotic integrity. Int. J. Colorectal Dis. 1992, 7, 141–143. [CrossRef]
107. Nicksa, G.A.; Dring, R.V.; Johnson, K.H.; Sardella, W.V.; Vignati, P.V.; Cohen, J.L. Anastomotic Leaks: What is the Best Diagnostic
Imaging Study? Dis. Colon Rectum 2007, 50, 197–203. [CrossRef]
108. Power, N.; Atri, M.; Ryan, S.; Haddad, R.; Smith, A. CT assessment of anastomotic bowel leak. Clin. Radiol. 2007, 62, 37–42.
[CrossRef]
109. Foster, M.E.; Laycock, J.R.D.; Silver, I.A.; Leaper, D.J. Hypovolaemia and healing in colonic anastomoses. BJS 1985, 72, 831–834.
[CrossRef]
110. Brandstrup, B.; Tønnesen, H.; Beier-Holgersen, R.; Hjortsø, E.; Ørding, H.; Lindorff-Larsen, K.; Rasmussen, M.S.; Lanng, C.;
Wallin, L.; Iversen, L.H. Effects of intravenous fluid restriction on postoperative complications: Comparison of two perioperative
fluid regimens: A randomized assessor-blinded multicenter trial. Ann. Surg. 2003, 238, 641–648. [CrossRef]
111. Kurz, A.; Sessler, D.I.; Lenhardt, R. Perioperative Normothermia to Reduce the Incidence of Surgical-Wound Infection and
Shorten Hospitalization. N. Engl. J. Med. 1996, 334, 1209–1216. [CrossRef] [PubMed]
112. Belda, F.J.; Aguilera, L.; De La Asunción, J.G.; Alberti, J.; Vicente, R.; Ferrándiz, L.; Rodríguez, R.; Sessler, D.I.; Aguilar, G.; Botello,
S.G. Supplemental perioperative oxygen and the risk of surgical wound infection: A randomized controlled trial. JAMA 2005,
294, 2035–2042. [CrossRef]
113. Gan, T.J.; Soppitt, A.; Maroof, M.; El-Moalem, H.; Robertson, K.M.; Moretti, E.; Dwane, P.; Glass, P.S.A. Goal-directed Intraop-
erative Fluid Administration Reduces Length of Hospital Stay after Major Surgery. J. Am. Soc. Anesthesiol. 2002, 97, 820–826.
[CrossRef]
114. Donati, A.; Loggi, S.; Preiser, J.-C.; Orsetti, G.; Munch, C.; Gabbanelli, V.; Pelaia, P.; Pietropaoli, P. Goal-Directed Intraoperative
Therapy Reduces Morbidity and Length of Hospital Stay in High-Risk Surgical Patients. Chest 2007, 132, 1817–1824. [CrossRef]
115. Kimberger, M.D.O.; Arnberger, M.D.M.; Brandt, M.D.S.; Plock, M.D.J.; Gisli, M.D.P.D.; Sigurdsson, H.; Kurz, M.D.A.; Hiltebrand,
M.D.L. Goal-directed Colloid Administration Improves the Microcirculation of Healthy and Perianastomotic Colon. Anesthesiology
2009, 110, 496–504. [CrossRef]
116. Ghasemi, M.; Nabipour, I.; Omrani, A.; Alipour, Z.; Assadi, M. Precision medicine and molecular imaging: New targeted
approaches toward cancer therapeutic and diagnosis. Am. J. Nucl. Med. Mol. Imaging 2016, 6, 310–327.
117. Katsnelson, A. Momentum grows to make ’personalized’ medicine more ’precise’. Nat. Med. 2013, 19, 249. [CrossRef]
118. National Research Council. The National Academies Collection: Reports Funded by National Institutes of Health, Toward Precision
Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease; National Academy of Sciences:
Washington, DC, USA, 2011.
119. Atkinson, A.J., Jr.; Colburn, W.A.; DeGruttola, V.G.; DeMets, D.L.; Downing, G.J.; Hoth, D.F.; Oates, J.A.; Peck, C.C.; Schooley, R.T.
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69, 89–95.
120. Mandrekar, S.J.; Sargent, D.J. Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical
Challenges. J. Clin. Oncol. 2009, 27, 4027–4034. [CrossRef]
121. Polley, M.-Y.C.; Freidlin, B.; Korn, E.L.; Conley, B.A.; Abrams, J.S.; McShane, L.M. Statistical and Practical Considerations for
Clinical Evaluation of Predictive Biomarkers. J. Natl. Cancer Inst. 2013, 105, 1677–1683. [CrossRef]
122. Ludwig, J.A.; Weinstein, J.N. Biomarkers in Cancer Staging, Prognosis and Treatment Selection. Nat. Rev. Cancer 2005, 5, 845–856.
[CrossRef]
123. Beard, J.D.; Nicholson, M.L.; Sayers, R.D.; Lloyd, D.; Everson, N.W. Intraoperative air testing of colorectal anastomoses: A
prospective, randomized trial. BJS 1990, 77, 1095–1097. [CrossRef] [PubMed]
124. Ivanov, D.; Cvijanovic, R.; Gvozdenovic, L. Intraoperative air testing of colorectal anastomoses. Srp. Arh. Za Celok. Lek. 2011, 139,
333–338. [CrossRef] [PubMed]
125. Li, V.K.M.; Wexner, S.D.; Pulido, N.; Wang, H.; Jin, H.Y.; Weiss, E.G.; Nogeuras, J.J.; Sands, D.R. Use of routine intraoperative
endoscopy in elective laparoscopic colorectal surgery: Can it further avoid anastomotic failure? Surg. Endosc. 2009, 23, 2459–2465.
[CrossRef] [PubMed]
126. Shamiyeh, A.; Szabo, K.; Wayand, W.U.; Zehetner, J. Intraoperative Endoscopy for the Assessment of Circular-stapled Anastomosis
in Laparoscopic Colon Surgery. Surg. Laparosc. Endosc. Percutaneous Tech. 2012, 22, 65–67. [CrossRef] [PubMed]
127. Brugiotti, C.; Corazza, V.; Peruzzi, A.; Lozano, C.; Casadevall, E.; Ques, F.; Ferrer, S.; Canaves, J.; Amurrio, R.; Rodriguez, J. The
efficacy of intraoperative endoscopic control of the colorectal stapled anastomosis after anterior resection of the rectum for rectal
cancer: P31. Colorectal Dis. 2011, 13, 31–32.
128. Karliczek, A.; Benaron, D.A.; Baas, P.C.; Zeebregts, C.J.; Wiggers, T.; Van Dam, G.M. Intraoperative assessment of microperfusion
with visible light spectroscopy for prediction of anastomotic leakage in colorectal anastomoses. Colorectal Dis. 2009, 12, 1018–1025.
[CrossRef]
J. Pers. Med. 2021, 11, 471 25 of 29
129. Hirano, Y.; Omura, K.; Tatsuzawa, Y.; Shimizu, J.; Kawaura, Y.; Watanabe, G. Tissue Oxygen Saturation during Colorectal Surgery
Measured by Near-infrared Spectroscopy: Pilot Study to Predict Anastomotic Complications. World J. Surg. 2006, 30, 457–461.
[CrossRef]
130. Kudszus, S.; Roesel, C.; Schachtrupp, A.; Höer, J.J. Intraoperative laser fluorescence angiography in colorectal surgery: A
noninvasive analysis to reduce the rate of anastomotic leakage. Langenbeck’s Arch. Surg. 2010, 395, 1025–1030. [CrossRef]
131. Boyle, N.; Manifold, D.; Jordan, M.; Mason, R. Intraoperative assessment of colonic perfusion using scanning laser doppler
flowmetry during colonic resection11No competing interests declared. J. Am. Coll. Surg. 2000, 191, 504–510. [CrossRef]
132. Servais, E.L.; Rizk, N.P.; Oliveira, L.; Rusch, V.W.; Bikson, M.; Adusumilli, P.S. Real-time intraoperative detection of tissue hypoxia
in gastrointestinal surgery by wireless pulse oximetry. Surg. Endosc. 2011, 25, 1383–1389. [CrossRef]
133. Myers, C.; Mutafyan, G.; Petersen, R.; Pryor, A.; Reynolds, J.; DeMaria, E. Real-time probe measurement of tissue oxygenation
during gastrointestinal stapling: Mucosal ischemia occurs and is not influenced by staple height. Surg. Endosc. 2009, 23, 2345–2350.
[CrossRef] [PubMed]
134. Salusjärvi, J.M.; Carpelan-Holmström, M.A.; Louhimo, J.M.; Kruuna, O.; Scheinin, T.M. Intraoperative colonic pulse oximetry in
left-sided colorectal surgery: Can it predict anastomotic leak? Int. J. Colorectal Dis. 2018, 33, 333–336. [CrossRef]
135. Cahill, A.R.; Mortensen, N.J. Intraoperative augmented reality for laparoscopic colorectal surgery by intraoperative near-infrared
fluorescence imaging and optical coherence tomography. Minerva Chir. 2010, 65, 451–462.
136. Matsui, A.; Winer, J.H.; Laurence, R.G.; Frangioni, J.V. Predicting the survival of experimental ischaemic small bowel using
intraoperative near-infrared fluorescence angiography. BJS 2011, 98, 1725–1734. [CrossRef]
137. Armstrong, G.; Croft, J.; Corrigan, N.; Brown, J.M.; Goh, V.; Quirke, P.; Hulme, C.; Tolan, D.; Kirby, A.; Cahill, R.; et al. IntAct:
Intra-operative fluorescence angiography to prevent anastomotic leak in rectal cancer surgery: A randomized controlled trial.
Colorectal Dis. 2018, 20, O226–O234. [CrossRef]
138. Shandall, A.; Lowndes, R.; Young, H.L. Colonic anastomotic healing and oxygen tension. BJS 2005, 72, 606–609. [CrossRef]
[PubMed]
139. Locke, R.; Hauser, C.J.; Shoemaker, W.C. The Use of Surface Oximetry to Assess Bowel Viability. Arch. Surg. 1984, 119, 1252.
[CrossRef] [PubMed]
140. Sheridan, W.G.; Lowndes, R.H.; Young, H.L. Intraoperative tissue oximetry in the human gastrointestinal tract. Am. J. Surg. 1990,
159, 314–319. [CrossRef]
141. Clifford, R.E.; Fowler, H.; Manu, N.; Sutton, P.; Vimalachandran, D. Intra-operative assessment of left-sided colorectal anastomotic
integrity: A systematic review of available techniques. Colorectal Dis. 2020, 23, 582–591. [CrossRef] [PubMed]
142. 2019 Safe-Anastomosis Programme in Colorectal Surgery (EAGLE). The European Society of Coloproctology. Available online:
https://www.escp.eu.com/research/cohort-studies/2019-escp-safe-anastomosis-programme-in-colorectal-surgery (accessed on
8 April 2021).
143. Corke, C.; Glenister, K. Monitoring intestinal ischaemia. Crit. Care Resusc. 2001, 3, 176–180.
144. Klaus, S.; Heringlake, M.; Gliemroth, J.; Bruch, H.-P.; Bahlmann, L. Intraperitoneal microdialysis for detection of splanchnic
metabolic disorders. Langenbeck’s Arch. Surg. 2002, 387, 276–280. [CrossRef]
145. Sommer, T.; Larsen, J.F. Intraperitoneal and intraluminal microdialysis in the detection of experimental regional intestinal
ischaemia. BJS 2004, 91, 855–861. [CrossRef]
146. Jansson, K.; Ungerstedt, J.; Jonsson, T.; Redler, B.; Andersson, M.; Ungerstedt, U.; Norgren, L. Human intraperitoneal microdialysis:
Increased lactate/pyruvate ratio suggests early visceral ischaemia. Scand. J. Gastroenterol. 2003, 38, 1007–1011.
147. Jansson, K.; Jansson, M.; Andersson, M.; Magnuson, A.; Ungerstedt, U.; Norgren, L. Normal values and differences between
intraperitoneal and subcutaneous microdialysis in patients after non-complicated gastrointestinal surgery. Scand. J. Clin. Lab.
Investig. 2005, 65, 273–282. [CrossRef]
148. Matthiessen, P.; Strand, I.; Jansson, K.; Törnquist, C.; Andersson, M.; Rutegård, J.; Norgren, L. Is Early Detection of Anastomotic
Leakage Possible by Intraperitoneal Microdialysis and Intraperitoneal Cytokines After Anterior Resection of the Rectum for
Cancer? Dis. Colon Rectum 2007, 50, 1918–1927. [CrossRef] [PubMed]
149. Pedersen, M.E.; Qvist, N.; Bisgaard, C.; Kelly, U.; Bernhard, A.; Pedersen, S.M. Peritoneal Microdialysis. Early diagnosis of
Anastomotic Leakage after Low Anterior Resection for Rectosigmoid Cancer. Scand. J. Surg. 2009, 98, 148–154. [CrossRef]
[PubMed]
150. Oikonomakis, I.; Jansson, D.; Hörer, T.M.; Skoog, P.; Nilsson, K.; Jansson, K. Results of postoperative microdialysis intraperitoneal
and at the anastomosis in patients developing anastomotic leakage after rectal cancer surgery. Scand. J. Gastroenterol. 2019, 54,
1261–1268. [CrossRef]
151. Hörer, T.M.; Norgren, L.; Jansson, K. Intraperitoneal glycerol levels and lactate/pyruvate ratio: Early markers of postoperative
complications. Scand. J. Gastroenterol. 2011, 46, 913–919. [CrossRef]
152. Bini, R.; Ferrari, G.; Aprà, F.; Viora, T.; Leli, R.; Cotogni, P. Peritoneal lactate as a potential biomarker for predicting the need for
reintervention after abdominal surgery. J. Trauma Acute Care Surg. 2014, 77, 376–380. [CrossRef]
153. Daams, F.; Wu, Z.; Cakir, H.; Karsten, T.M.; Lange, J.F. Identification of anastomotic leakage after colorectal surgery using
microdialysis of the peritoneal cavity. Tech. Coloproctol. 2013, 18, 65–71. [CrossRef]
154. Ellebæk, M.B.; Rahr, H.B.; Boye, S.; Fristrup, C.; Qvist, N. Detection of early anastomotic leakage by intraperitoneal microdialysis
after low anterior resection for rectal cancer: A prospective cohort study. Colorectal Dis. 2019, 21, 1387–1396. [CrossRef] [PubMed]
J. Pers. Med. 2021, 11, 471 26 of 29
155. Millan, M.; García-Granero, E.; Flor, B.; García-Botello, S.; Lledo, S. Early prediction of anastomotic leak in colorectal cancer
surgery by intramucosal pH. Dis. Colon Rectum 2006, 49, 595–601. [CrossRef] [PubMed]
156. Yang, L.; Huang, X.-E.; Xu, L.; Zhou, X.; Zhou, J.-N.; Yu, D.-S.; Li, D.-Z.; Guan, X. Acidic Pelvic Drainage as a Predictive Factor
For Anastomotic Leakage after Surgery for Patients with Rectal Cancer. Asian Pac. J. Cancer Prev. 2013, 14, 5441–5447. [CrossRef]
[PubMed]
157. Marland, J.R.K.; Gray, M.E.; Dunare, C.; Blair, E.O.; Tsiamis, A.; Sullivan, P.; González-Fernández, E.; Greenhalgh, S.N.; Gregson,
R.; Clutton, R.E.; et al. Real-time measurement of tumour hypoxia using an implantable microfabricated oxygen sensor. Sens.
Bio-Sens. Res. 2020, 30, 1–12.
158. Marland, J.R.K.; Blair, E.O.; Flynn, B.W.; González-Fernández, E.; Huang, L.; Kunkler, I.H.; Smith, S.; Staderini, M.; Tsiamis,
A.; Ward, C.; et al. Implantable Microsystems for Personalised Anticancer Therapy. In CMOS Circuits for Biological Sensing and
Processing; Mitra, S., Cumming, D.R.S., Eds.; Springer International Publishing: Cham, Switzerland, 2018; pp. 259–286.
159. Gray, M.E.; Marland, J.R.K.; Dunare, C.; Blair, E.O.; Meehan, J.; Tsiamis, A.; Kunkler, I.H.; Murray, A.F.; Argyle, D.; Dyson, A.;
et al. In vivo validation of a miniaturized electrochemical oxygen sensor for measuring intestinal oxygen tension. Am. J. Physiol.
Liver Physiol. 2019, 317, G242–G252. [CrossRef]
160. Badia, J.M.; Whawell, S.A.; Scott-Coombes, D.M.; Abel, P.D.; Williamson, R.C.N.; Thompson, J.N. Peritoneal and systemic
cytokine response to laparotomy. BJS 1996, 83, 347–348. [CrossRef]
161. Welsch, T.; Müller, S.A.; Ulrich, A.; Kischlat, A.; Hinz, U.; Kienle, P.; Büchler, M.W.; Schmidt, J.; Schmied, B.M. C-reactive protein
as early predictor for infectious postoperative complications in rectal surgery. Int. J. Colorectal Dis. 2007, 22, 1499–1507. [CrossRef]
162. Matthiessen, P.; Henriksson, M.; Hallböök, O.; Grunditz, E.; Norén, B.; Arbman, G. Increase of serum C-reactive protein is an
early indicator of subsequent symptomatic anastomotic leakage after anterior resection. Colorectal Dis. 2007, 10, 75–80. [CrossRef]
163. Woeste, G.; Müller, C.; Bechstein, W.O.; Wullstein, C. Increased Serum Levels of C-Reactive Protein Precede Anastomotic Leakage
in Colorectal Surgery. World J. Surg. 2009, 34, 140–146. [CrossRef]
164. Pedersen, T.; Roikjær, O.; Jess, P. Increased levels of C-reactive protein and leukocyte count are poor predictors of anastomotic
leakage following laparoscopic colorectal resection. Dan. Med. J. 2012, 59, 1–4.
165. Almeida, A.; Faria, G.; Moreira, H.; Pinto-De-Sousa, J.; Correia-Da-Silva, P.; Maia, J.C. Elevated serum C-reactive protein as a
predictive factor for anastomotic leakage in colorectal surgery. Int. J. Surg. 2012, 10, 87–91. [CrossRef]
166. Lagoutte, N.; Facy, O.; Ravoire, A.; Chalumeau, C.; Jonval, L.; Rat, P.; Ortega-Deballon, P. C-reactive protein and procalcitonin for
the early detection of anastomotic leakage after elective colorectal surgery: Pilot study in 100 patients. J. Visc. Surg. 2012, 149,
e345–e349. [CrossRef]
167. Reisinger, K.W.; Poeze, M.; Hulsewé, K.W.; van Acker, B.A.; van Bijnen, A.A.; Hoofwijk, A.G.; Stoot, J.; Derikx, J.P. Accurate
Prediction of Anastomotic Leakage after Colorectal Surgery Using Plasma Markers for Intestinal Damage and Inflammation. J.
Am. Coll. Surg. 2014, 219, 744–751. [CrossRef]
168. Zawadzki, M.; Czarnecki, R.; Rzaca, M.; Obuszko, Z.; Velchuru, V.R.; Witkiewicz, W. C-reactive protein and procalcitonin predict
anastomotic leaks following colorectal cancer resections–a prospective study. Videosurg. Other Miniinvasive Tech. 2015, 10, 567.
[CrossRef]
169. Waterland, P.; Ng, J.; Jones, A.; Broadley, G.; Nicol, D.; Patel, H.; Pandey, S. Using CRP to predict anastomotic leakage after open
and laparoscopic colorectal surgery: Is there a difference? Int. J. Colorectal Dis. 2016, 31, 861–868. [CrossRef]
170. Giaccaglia, V.; Salvi, P.F.; Antonelli, M.S.; Nigri, G.R.; Corcione, F.; Pirozzi, F.; De Manzini, N.; Casagranda, B.; Balducci, G.; Ziparo,
V. Procalcitonin reveals early dehiscence in colorectal surgery: The PREDICS study. J. Am. Coll. Surg. 2014, 219, e8. [CrossRef]
171. Mik, M.; Dziki, L.; Berut, M.; Trzcinski, R.; Dziki, A. Neutrophil to Lymphocyte Ratio and C-Reactive Protein as Two Predictive
Tools of Anastomotic Leak in Colorectal Cancer Open Surgery. Dig. Surg. 2017, 35, 77–84. [CrossRef]
172. Smith, S.R.; Pockney, P.; Holmes, R.; Doig, F.; Attia, J.; Holliday, E.; Carroll, R.; Draganic, B. Biomarkers and anastomotic leakage
in colorectal surgery: C-reactive protein trajectory is the gold standard. ANZ J. Surg. 2018, 88, 440–444. [CrossRef]
173. Reynolds, I.S.; Boland, M.R.; Reilly, F.; Deasy, A.; Majeed, M.H.; Deasy, J.; Burke, J.P.; McNamara, D.A. C-reactive protein as a
predictor of anastomotic leak in the first week after anterior resection for rectal cancer. Colorectal Dis. 2017, 19, 812–818. [CrossRef]
174. Warschkow, R.; Tarantino, I.; Torzewski, M.; Näf, F.; Lange, J.; Steffen, T. Diagnostic accuracy of C-reactive protein and white
blood cell counts in the early detection of inflammatory complications after open resection of colorectal cancer: A retrospective
study of 1187 patients. Int. J. Colorectal Dis. 2011, 26, 1405–1413. [CrossRef]
175. Kørner, H.; Nielsen, H.J.; Søreide, J.A.; Nedrebø, B.S.; Søreide, K.; Knapp, J.C. Diagnostic Accuracy of C-reactive Protein for
Intraabdominal Infections After Colorectal Resections. J. Gastrointest. Surg. 2009, 13, 1599–1606. [CrossRef] [PubMed]
176. Ho, Y.M.; Laycock, J.; Kirubakaran, A.; Hussain, L.; Clark, J. Systematic use of the serum C-reactive protein concentration and
computed tomography for the detection of intestinal anastomotic leaks. ANZ J. Surg. 2019, 90, 109–112. [CrossRef] [PubMed]
177. Messias, B.A.; Botelho, R.V.; Saad, S.S.; Mocchetti, E.R.; Turke, K.C.; Waisberg, J. Serum C-reactive protein is a useful marker to
exclude anastomotic leakage after colorectal surgery. Sci. Rep. 2020, 10, 1–8. [CrossRef]
178. Singh, P.P.; Zeng, I.S.; Srinivasa, S.; Lemanu, D.P.; Connolly, A.B.; Hill, A.G. Systematic review and meta-analysis of use of serum
C-reactive protein levels to predict anastomotic leak after colorectal surgery. BJS 2014, 101, 339–346. [CrossRef]
179. Stephensen, B.; Reid, F.; Shaikh, S.; Carroll, R.; Smith, S.; Pockney, P. C-reactive protein trajectory to predict colorectal anastomotic
leak. Br. J. Surg. 2020, 107, 1832–1837. [CrossRef] [PubMed]
J. Pers. Med. 2021, 11, 471 27 of 29
180. Hübner, M.; Mantziari, S.; Demartines, N.; Pralong, F.; Coti-Bertrand, P.; Schäfer, M. Postoperative Albumin Drop Is a Marker for
Surgical Stress and a Predictor for Clinical Outcome: A Pilot Study. Gastroenterol. Res. Pract. 2016, 2016, 1–8. [CrossRef]
181. Lago, V.; Fotopoulou, C.; Chiantera, V.; Minig, L.; Gil-Moreno, A.; Cascales-Campos, P.; Jurado, M.; Tejerizo, A.; Padilla-Iserte, P.;
Malune, M.; et al. Risk factors for anastomotic leakage after colorectal resection in ovarian cancer surgery: A multi-centre study.
Gynecol. Oncol. 2019, 153, 549–554. [CrossRef]
182. Ge, X.; Cao, Y.; Wang, H.; Ding, C.; Tian, H.; Zhang, X.; Gong, J.; Zhu, W.; Li, N. Diagnostic accuracy of the postoperative ratio of
C-reactive protein to albumin for complications after colorectal surgery. World J. Surg. Oncol. 2017, 15, 1–7. [CrossRef]
183. Yu, Y.; Wu, Z.; Shen, Z.; Cao, Y. Preoperative C-reactive protein-to-albumin ratio predicts anastomotic leak in elderly patients
after curative colorectal surgery. Cancer Biomark. 2020, 27, 295–302. [CrossRef]
184. Maruna, P.; Nedelníková, K.; Gürlich, R. Physiology and genetics of procalcitonin. Physiol. Res. 2000, 49, S57–S62. [PubMed]
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